



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 172817

TO: Timothy M Brown
Location: REM/3C31/3C18
Art Unit: 1648
Tuesday, December 06, 2005

Case Serial Number: 10/622124

From: Edward Hart
Location: Biotech-Chem Library
REM-1A55
Phone: 571-272-2512

edward.hart@uspto.gov

Search Notes

Examiner Brown,

Here are the results of the search you requested.

Please feel free to contact me if you have any questions.

Edward Hart

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: December 3, 2005, 13:04:21, Search time 233 Seconds
(without alignments)
84,785 Million cell updates/sec

Title: US-10-622-124-31

Perfect score: 145
Sequence: 1 GSSFLSPHQHVQQRKSKPPAKLQPR 28

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Uniprot 05.80:*
1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	145	100.0	91	Q86YP8_HUMAN	Q86YP8 homo sapien
2	145	100.0	117	Q86YP8_HUMAN	Q86YP8 homo sapien
3	142	97.9	117	Q86YP8_HUMAN	Q86YP8 homo sapien
4	141	97.2	117	Q86YP8_HUMAN	Q86YP8 homo sapien
5	139	95.9	117	Q86YP8_HUMAN	Q86YP8 homo sapien
6	138	95.2	86	Q86YP8_HUMAN	Q86YP8 homo sapien
7	138	95.2	117	Q86YP8_HUMAN	Q86YP8 homo sapien
8	138	95.2	117	Q86YP8_HUMAN	Q86YP8 homo sapien
9	138	95.2	117	Q86YP8_HUMAN	Q86YP8 homo sapien
10	130	89.7	65	Q86YP8_HUMAN	Q86YP8 homo sapien
11	130	89.7	74	Q86YP8_HUMAN	Q86YP8 homo sapien
12	130	89.7	118	Q86YP8_HUMAN	Q86YP8 homo sapien
13	101.5	70.0	54	Q86YP8_HUMAN	Q86YP8 homo sapien
14	101.5	70.0	54	Q86YP8_HUMAN	Q86YP8 homo sapien
15	101.5	70.0	116	Q86YP8_HUMAN	Q86YP8 homo sapien
16	99.5	68.6	52	Q86YP8_HUMAN	Q86YP8 homo sapien
17	99.5	68.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
18	99.5	68.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
19	99.5	68.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
20	99.5	68.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
21	99.5	68.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
22	99.5	68.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
23	99.5	68.6	97	Q86YP8_HUMAN	Q86YP8 homo sapien
24	99.5	68.6	116	Q86YP8_HUMAN	Q86YP8 homo sapien
25	99.5	68.6	116	Q86YP8_HUMAN	Q86YP8 homo sapien
26	96.5	66.6	54	Q86YP8_HUMAN	Q86YP8 homo sapien
27	94	64.8	116	Q86YP8_HUMAN	Q86YP8 homo sapien
28	91	62.8	116	Q86YP8_HUMAN	Q86YP8 homo sapien
29	85	58.6	116	Q86YP8_HUMAN	Q86YP8 homo sapien
30	85	58.6	116	Q86YP8_HUMAN	Q86YP8 homo sapien
31	81.5	56.2	35	Q86YP8_HUMAN	Q86YP8 homo sapien

32	78	53.8	114	2	Q6F4B4_TRASC	Q6F4B4 trachemys s
33	78	53.8	124	2	Q6F4B3_TRASC	Q6F4B3 trachemys s
34	73	50.3	116	2	Q6VMJ6_ANAPL	Q6VMJ6 anas platyr
35	73	50.3	116	2	Q6VMJ7_ANAPL	Q6VMJ7 anas platyr
36	67	46.2	36	2	Q5Y392_HUMAN	Q5Y392 homo sapien
37	67	46.2	36	2	Q5Y392_HUMAN	Q5Y392 homo sapien
38	58	40.0	194	2	Q5GYB2_XANOR	Q5GYB2 xanthomomas
39	58	40.0	267	2	Q8BZP7_MOUSE	Q8BZP7 mus musculu
40	58	40.0	309	2	Q5H4X5_XANOR	Q5H4X5 xanthomomas
41	58	40.0	379	2	Q5H202_XANOR	Q5H202 xanthomomas
42	58	40.0	410	2	Q5H562_XANOR	Q5H562 xanthomomas
43	58	40.0	430	2	Q5H1Q5_XANOR	Q5H1Q5 xanthomomas
44	58	40.0	432	2	Q5H3Q4_XANOR	Q5H3Q4 xanthomomas
45	58	40.0	434	2	Q5H293_XANOR	Q5H293 xanthomomas

ALIGNMENTS

```

RESULT 1
ID Q86YP8_HUMAN PRELIMINARY; PRT; 91 AA.
AC Q86YP8;
DT 01-JUN-2003 (TREMBLrel. 24, Created)
DT 01-JUN-2003 (TREMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)
DE Exon 3-deleted preproghrelin variant.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae;
OC Homo.
NCBI_Taxid=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Jeffery P. L., Herington A. C., Chopin L. K.;
RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY184207; AA027351.1; -; mRNA.
DR Ensembl; ENSG00000157017; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0016608; F:growth hormone-releasing hormone activity; IEA.
DR GO; GO:0050791; P:regulation of physiological process; IEA.
DR InterPro; IPR006738; motifin ghrelin.
DR InterPro; IPR005441; Preproghrelin.
DR PANTHER; PTHR14122; Preproghrelin; 1.
DR Pfam; PF04644; Motilin_ghrelin; 1.
DR PRINTS; PR01624; GHRELIN.
SQ
SEQUENCE 91 AA; 9972 MW; E7E532D32A3F8609 CRC64;

Query Match          100.0%; Score 145; DB 2; Length 91;
Best Local Similarity 100.0%; Pred. No. 1e-11;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GSSFLSPHQHVQQRKSKPPAKLQPR 28
Db 24 GSSFLSPHQHVQQRKSKPPAKLQPR 51

RESULT 2
ID Q86YP8_HUMAN STANDARD; PRT; 117 AA.
AC Q86YP8;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Ghrelin precursor (Growth hormone secretagogue) (Growth hormone
DE releasing peptide) (Motilin-related peptide) (M46 protein) [Contains:
DE Ghrelin-27; Ghrelin-28 (Ghrelin)].
GN Name=GhRL; Synonym=MTLR; ORFNames=UNQ524/PRO1066;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae;
OC Homo.
NCBI_Taxid=9606;

```

RN [1]
 RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ACYLATION OF SER-26.
 RC TISSUE=Stomach;
 RX MEDLINE=20067959; PubMed=10604470; DOI=10.1038/45230;
 RA Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K.;
 RT "Ghrelin is a growth-hormone-releasing acylated peptide from stomach.";
 RL Nature 402:656-660(1999).
 RN [2]
 RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 24-33.
 RC TISSUE=Stomach;
 RX MEDLINE=2038976; PubMed=10930375;
 RA Tomasetto C., Karim S.M., Ribieras S., Masson R., Lefebvre O.,
 Staub A., Alexander G., Chenard M.-P., Rio M.-C.;
 RT "Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide.";
 RL Gastroenterology 119:395-405(2000).
 RN [3]
 RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
 RA Wajsbach M.P., Ten I.S., Gertner J.M., Leibel R.L.;
 RT "Genomic organization of the human Ghrelin gene.";
 RL J. Endocr. Genet. 1:231-233(2000).
 RN [4]
 RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, ACYLATION OF SER-26, AND MASS SPECTROMETRY.
 RC TISSUE=Stomach;
 RX PubMed=12414809; DOI=10.1074/jbc.M205366200;
 RA Hosoda H., Kojima M., Mizushima T., Shimizu S., Kangawa K.;
 RT "Structural divergence of human ghrelin. Identification of multiple ghrelin-derived molecules produced by post-translational processing.";
 RL J. Biol. Chem. 278:64-70(2003).
 RN [5]
 RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
 RX MEDLINE=22887296; PubMed=12975309; DOI=10.1101/gr.1293003;
 RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C., Curriel B., Dezel B., Dowd P., Eaton D., Foster J.S., Grimaldi C., Gu Q., Haas P.E., Heldens S., Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seehagiri S., Simmons L., Singh V., Smith J., Stinson J., Vagts A., Vanden R.L., Watanabe C., Wiand D., Woods K., Xie M.-H., Yaneura D.G., Yi S., Yu G., Yuan J., Zhang W., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
 RT "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment.";
 RL Genome Res. 13:2265-2270(2003).
 RN [6]
 RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
 RC TISSUE=Blood;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Struhsberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Scheinen C.M., Schuler G.D., Altshul S.F., Zeeberg B., Buetow K.H., Scheiner C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Murusana K., Farmer A.A., Rubin G.M., Hong L., Stjepanec M., Soares M.B., Bonaldi M.F., Casarini T.L., Scheetz T.E., Brownstein M.J., Ueda T.B., Toshiyuki S., Caranti P., Prange C., Raha S.S., Loguallano N.A., Peters G.J., Abramson R.D., Mullany S.J., Bosak S.A., McEwen P.J., McKernan K.J., Malek A.M., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villallon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Roderfeldt Y.S.N., Krzywinski M.I., Skalska U., Smalins D.E., Scherch A.J., Schein J.E., Jones S.J.M., Marra M.A.;
 RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [7]
 RP PROTEIN SEQUENCE OF 24-38.

RX PubMed=15340161; DOI=10.1110/ps.04682504;
 RA Zhang Z., Henzel W.J.;
 RT "Signal peptide prediction based on analysis of experimentally verified cleavage sites.";
 RL Protein Sci. 13:2819-2824(2004).
 RN [8]
 RP REVIEW.
 RX MEDLINE=21203998; PubMed=11306336; DOI=10.1016/S1043-2760(00)00362-3;
 RA Kojima M., Hosoda H., Matsuo H., Kangawa K.;
 RT "Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor.";
 RL Trends Endocrinol. Metab. 12:118-122(2001).
 CC 1- FUNCTION: Specific ligand for the growth hormone secretagogue receptor type 1 (GHSR) inducing the release of growth hormone from the pituitary. Has an appetite-stimulating effect, induces adiposity and stimulates gastric acid secretion. Involved in growth regulation.
 CC 1- SUBCELLULAR LOCATION: Secreted.
 CC 1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=1; Synonym=Ghrelin;
 CC IsoId=Q9UBU3-1; Sequence=Displayed;
 CC Name=2; Synonym=del-Gln14-ghrelin;
 CC IsoId=Q9UBU3-2; Sequence=VSP_003245;
 CC 1- TISSUE SPECIFICITY: Highest level in stomach. All forms are found in serum as well. Other tissues compensate for the loss of ghrelin synthesis in the stomach following gastrectomy.
 CC 1- PM: O-n-octanoylation is essential for activity. The O-n-decanoylated forms Ghrelin-27-C10 and Ghrelin-28-C10 differ in the length of the carbon backbone of the carboxylic acid bound to Ser-26. A small fraction of Ghrelin, ghrelin-28-C10:1, may be modified with an unsaturated carboxylic acid.
 CC 1- MASS SPECTROMETRY: MM=3398.9; MW ERR=0.3; METHOD=Electrospray;
 CC RANGE=24-51 (Ghrelin-28-C10); NOTE=O-decanoylated form (Ref.4).
 CC 1- MASS SPECTROMETRY: MM=3397.2; MW ERR=0.5; METHOD=Electrospray;
 CC RANGE=24-51 (Ghrelin-28-C10:1); NOTE=O-decanoylated form (Ref.4).
 CC 1- MASS SPECTROMETRY: MM=3371.3; MW ERR=0.1; METHOD=Electrospray;
 CC RANGE=24-51 (Ghrelin-28); NOTE=O-octanoylated form (Ref.4).
 CC 1- MASS SPECTROMETRY: MM=3243.6; MW ERR=0.4; METHOD=Electrospray;
 CC RANGE=24-50 (Ghrelin-27-C10); NOTE=O-decanoylated form (Ref.4).
 CC 1- MASS SPECTROMETRY: MM=3214.6; MW ERR=0.6; METHOD=Electrospray;
 CC RANGE=24-50 (Ghrelin-27); NOTE=O-octanoylated form (Ref.4).
 CC 1- SIMILARITY: Belongs to the motilin family.
 CC 1- DATABAS: NAME=Atlas Genet. Cytogenet. Oncol. Haematol.;
 CC MW="http://www.infobio.gen.fr/services/chromosome/Genes/GhrelinID327.html".
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.
 CC EMBL; AB029434; BAA89371.1; -; mRNA.
 CC EMBL; AJ252278; CAB65733.1; -; mRNA.
 CC EMBL; AF296558; AAG10300.1; -; Genomic DNA.
 CC EMBL; AB035700; BAB19045.1; -; mRNA.
 CC EMBL; AY359053; AAC899412.1; -; mRNA.
 CC EMBL; BC025791; AAB5791.1; -; mRNA.
 CC PIR; A59316; A59316.
 CC PDB; 1P7X; Model; A=1-117.
 CC Ensembl; ENSG00000157017; Homo sapiens.
 CC H-InvDB; HIX003050; -.
 CC MIM; 605353; -.
 CC GO; GO:0005615; C:extracellular space; ISS.
 CC GO; GO:0001664; F:G-protein-coupled receptor binding; ISS.
 CC GO; GO:0016608; F:growth hormone-releasing hormone activity; ISS.
 CC GO; GO:0007186; P:G-protein coupled receptor protein signaling. . .; ISS.
 CC GO; GO:0050791; P:regulation of physiological process; ISS.
 CC InterPro; IPR006737; motilin assoc.
 CC InterPro; IPR006738; motilin_ghrelin.
 CC InterPro; IPR005441; Preproghrelin.
 CC PANTHER; PTHR14122; Preproghrelin; 1.
 CC Pfam; PF04643; Motilin_assoc; 1.

```

DR Pfam; PF04644; Motilin_ghrelin; 1.
DR PRINTS; PR01624; GHRELIN.
DR Prodom; PD332162; Preproghrelin; 1.
DR 3D-structure; Alternative splicing; Direct protein sequencing;
KW Hormone; Lipoprotein; Signal.
FT SIGNAL 1 23 Ghrelin-28.
FT PEPTIDE 24 51 Ghrelin-27.
FT PROPEP 52 117 Removed in mature form.
FT LIPID 26 26 O-decanoyl serine (in form ghrelin-27-C10
and form ghrelin-28-C10).
FT LIPID 26 26 O-octanoyl serine (in form ghrelin-27 and
form ghrelin-28).
FT VARSPLIC 37 37 Missing (in isoform 2).
FT CONFLICT 72 72 /FTid=VSP_003245.
FT SEQUENCE 117 AA; 12911 MW; 39C0572EBBCA2755 CRC64;

Query Match 100.0%; Score 145; DB 1; Length 117;
Best Local Similarity 100.0%; Pred. No. 1.3e-11;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
Db 24 GSSFLSPHQHVQQRKSKKPPAKLQPR 51

RESULT 3
GHR_L_PELCA STANDARD; PRT; 117 AA.
AC Q6BEG6; Q6BEG5;
DT 25-OCT-2004 (Rel. 45, Created)
DT 25-OCT-2004 (Rel. 45, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Ghrelin precursor (Growth hormone secretagogue) (Growth hormone
releasing peptide) (Motilin-related peptide).
GN Name=GHR_L;
OS Felle silvestris catus (Cat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Felidae;
OC Felinae; Felis.
OC NCBI_TaxId=9685;
RN [1]
RP NUCLEOTIDE SEQUENCE (MRNA) (ISOFORMS 1 AND 2).
RC TISSUE=Stomach;
RA Lin X., Miyazato M., Kaiya H., Ida T., Kangawa K.;
RT "cDNA cloning of feline and caprine ghrelin.";
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
CC -1- FUNCTION: Specific ligand for the growth hormone secretagogue
receptor type 1 (GHSR) inducing the release of growth hormone from
the pituitary. Has an appetite-stimulating effect, induces
adiposity and stimulates gastric acid secretion. Involved in
growth regulation (By similarity).
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1; Synonym=Chrelin;
CC IsoId=Q6BEG6-1; Sequence=displayed;
CC Name=2; Synonym=del-Gln14-ghrelin;
CC IsoId=Q6BEG6-2; Sequence=VSP_011626;
CC -1- PTM: O-n-octanoylation is essential for activity (By similarity).
CC -1- SIMILARITY: Belongs to the motilin family.
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use as long as its content is in no way modified and this statement is not
removed.
CC EMBL; AB089201; BAD34670.1; -; mRNA.
CC EMBL; AB089202; BAD34671.1; -; mRNA.
CC InterPro; IPR006737; motilin_assoc
CC InterPro; IPR006738; motilin_ghrelin.

```

```

DR InterPro; IPR005441; Preproghrelin.
DR PANTHER; PTHR14122; Preproghrelin; 1.
DR Pfam; PF04643; Motilin_assoc; 1.
DR Pfam; PF04644; Motilin_ghrelin; 1.
DR PRINTS; PR01624; GHRELIN.
DR Prodom; PD332162; Preproghrelin; 1.
DR Alternative splicing; Hormone; Lipoprotein; Signal.
FT SIGNAL 1 23 Ghrelin (By similarity).
FT PEPTIDE 24 51 Ghrelin (By similarity).
FT PROPEP 52 117 Removed in mature form (By similarity).
FT LIPID 26 26 O-octanoyl serine (By similarity).
FT VARSPLIC 37 37 Missing (in isoform 2).
FT SEQUENCE 117 AA; 12956 MW; 8235A51447FF530 CRC64;

Query Match 97.9%; Score 142; DB 1; Length 117;
Best Local Similarity 96.4%; Pred. No. 3.4e-11;
Matches 27; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
Db 24 GSSFLSPHQHVQQRKSKKPPAKLQPR 51

RESULT 4
Q6UDE7_MACMU PRELIMINARY; PRT; 117 AA.
AC Q6UDE7;
DT 05-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 01-FEB-2005 (TREMBLrel. 29, Last annotation update)
DE Ghrelin.
GN Name=GHR_L;
OS Macaca mulatta (Rhesus macaque).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
OC Cercopitheidae; Cercopitheinae; Macaca.
OC NCBI_TaxId=9544;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=14736731; DOI=10.1210/en.2003-1103;
RA Angeloni S.V., Glynn N., Ambrosini G., Garrant M.J., Dee Hingley J.,
RA Suoni S., Hansen B.C.;
RT "Characterization of the rhesus monkey ghrelin gene and factors
influencing ghrelin gene expression and fasting plasma levels.";
RL Endocrinology 145:2197-2205(2004).
DR EMBL; AY372274; AAQ74837.1; -; Genomic_DNA.
DR EMBL; AY371699; AAQ74381.1; -; mRNA.
DR GO; GO:0005576; C:extracellular region; IEA.
DR GO; GO:0016068; F:growth hormone-releasing hormone activity; IEA.
DR GO; GO:0050791; P:regulation of physiological process; IEA.
DR InterPro; IPR006737; motilin_assoc.
DR InterPro; IPR006738; motilin_ghrelin.
DR InterPro; IPR005441; Preproghrelin.
DR PANTHER; PTHR14122; Preproghrelin; 1.
DR Pfam; PF04643; Motilin_assoc; 1.
DR Pfam; PF04644; Motilin_ghrelin; 1.
DR PRINTS; PR01624; GHRELIN.
DR Prodom; PD332162; Preproghrelin; 1.
DR SEQUENCE 117 AA; 12913 MW; 1B634ACE1E1F19FF CRC64;

Query Match 97.2%; Score 141; DB 2; Length 117;
Best Local Similarity 96.4%; Pred. No. 4.6e-11;
Matches 27; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
Db 24 GSSFLSPHQHVQQRKSKKPPAKLQPR 51

RESULT 5
GHR_L_CANFA STANDARD; PRT; 117 AA.
ID GHR_L_CANFA

```

```

AC 09BEF8_09BEF7:
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 13-SEP-2005 (Rel. 48, Last annotation update)
DE Ghrelin precursor (Growth hormone secretagogue) (Growth hormone
DE releasing peptide) (Motilin-related peptide).
GN Name=GhRL; Synonyms=MTLRL;
OS Canis familiaris (Dog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Laurasiatheria; Carnivora; Fissipedia; Canidae;
OC Canis.
OX NCBI_TaxID=9615;
RN [1]
RP NUCLEOTIDE SEQUENCE [mRNA] (ISOFORMS 1 AND 2).
RC TISSU=gastric fundus;
RA Tomasetto C., Wendling C., Rio M.-C., Poltras P.;
RT "Identification of cDNA encoding MTLRP/ghrelin precursor from dog
RT fundus."
RL Submitted (JAN-2001) to the EMBL/GenBank/DBD databases.
RN [2]
RP NUCLEOTIDE SEQUENCE [mRNA] (ISOFORM 1).
RC TISSU=Stomach;
RA Doi K., Kojima M., Hosoda H., Kaiya H., Matsuo H., Kangawa K.;
RT "Dog ghrelin."
RL Submitted (APR-2001) to the EMBL/GenBank/DBD databases.
CC -1- FUNCTION: Specific ligand for the growth hormone secretagogue
CC receptor type 1 (GHSR) inducing the release of growth hormone from
CC the pituitary. Has an appetite-stimulating effect, induces
CC adiposity and stimulates gastric acid secretion. Involved in
CC growth regulation (By similarity).
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1; Synonyms=Ghrelin;
CC IsoId=G9BEF8-1; Sequence=Displayed;
CC Name=2; Synonyms=del-Gln14-ghrelin;
CC IsoId=G9BEF8-2; Sequence=VSP_003244;
CC -1- PTM: O-n-octanoylation is essential for activity (By similarity).
CC -1- SIMILARITY: Belongs to the motilin family.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC DR EMBL; AJ298295; CAC29155.1; -; mRNA.
CC DR EMBL; AJ298296; CAC29156.1; -; mRNA.
CC DR EMBL; AB060700; BAC75928.1; -; mRNA.
CC DR EMBL; E0584F00000005129; Canis familiaris.
CC DR InterPro; IPR006737; motilin_aseoc.
CC DR InterPro; IPR006738; motilin_ghrelin.
CC DR InterPro; IPR005441; Preproghrelin.
CC DR PANTHER; PTHR14122; Preproghrelin; 1.
CC DR Pfam; PF04643; Motilin_aseoc; 1.
CC DR Pfam; PF04644; Motilin_ghrelin; 1.
CC DR PRINTS; PR01624; GHRELIN.
CC DR ProDom; PD332162; Preproghrelin; 1.
CC DR SIGNAL.
CC FT SIGNAL. 1 23 By similarity.
CC FT PEPTIDE. 24 51 Ghrelin (By similarity).
CC FT PROSEP. 52 117 Removed in mature form (By similarity).
CC FT LIPID. 26 26 O-octanoyl serine (By similarity).
CC FT VARSPPLIC. 37 37 Missing (in isoform 2).
CC FT FTId=VSP_003244.
CC FT FTId=VSP_003244.
CC
CC SEQUENCE 117 AA, 13007 MW, 3557FBD5D1847CF7 CRC64;
Query Match 95.9%; Score 139; DB 1; Length 117;
Best Local Similarity 92.9%; Pred. No. 8, 6e-11;
Matches 26; Conservative 2; Mismatches 0; Indels 0; Gaps 0,
1 GSSFLSPFHQVQQRKSKKPKAKQPR 28
|||||

```

DB	24	GSSFLSPENHQLOQRKESKPKPAKLQPR	51
RESULT 6			
ID	081174	MOUSE PRELIMINARY;	PRT; 86 AA.
AC	081174		
DT	01-JUN-2003	(TREMBLrel. 24, Created)	
DT	01-JUN-2003	(TREMBLrel. 24, Last sequence update)	
DE	01-MAR-2004	(TREMBLrel. 26, Last annotation update)	
EN	Exon 4-deleted preproghrelin variant.		
GN	Name=Ghr1;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;		
OC	Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		
RN	[1]		
RP	NUCLEOTIDE SEQUENCE.		
RC	STRAIN=Swiss;		
RX	PubMed=15471962; DOI=10.1210/en.2003-1466;		
RX	Jeffery P.L., Duncan R.P., Yeh A.H., Jaskolski R.A., Hammond D.S.,		
RA	Herrington A.C., Chopin L.K.;		
RT	"Expression of the ghrelin axis in the mouse: an exon 4-deleted mouse		
RL	proghrelin variant encodes a novel C terminal peptide.";		
RL	Endocrinology 146:432-440(2005).		
DR	EMBL; AY179430; AAC27350.1; -; mRNA.		
DR	Ensembl; ENSMUSG0000064177; Mus musculus.		
DR	MGI; MGI:193008; Ghr1.		
DR	GO; GO:0005737; Cytoplasm; IDA.		
DR	GO; GO:0005615; Extracellular space; TAS.		
DR	GO; GO:0005179; Hormone activity; TAS.		
DR	InterPro; IPR006738; motilin_ghrelin.		
DR	InterPro; IPR005441; Preproghrelin.		
DR	PANTHER; PTHR41422; Preproghrelin; 1.		
DR	Pfam; PF04644; Motilin_ghrelin; 1.		
DR	PRINTS; PRO1624; GHRELIN.		
SQ	SEQUENCE 86 AA; 9758 MW; B913858674770512 CRC64;		
Query Match 95.2%; Score 138; DB 2; Length 86;			
Best Local Similarity 92.9%; Pred. No. 8.4e-11;			
Matches	26;	Conservative 1;	Mismatches 1; Indels 0; Gaps 0;
QY	1	GSSFLSPENHQLOQRKESKPKPAKLQPR	28
DB	24	GSSFLSPENHQLOQRKESKPKPAKLQPR	51
RESULT 7			
ID	GHR1_MOUSE	STANDARD;	PRT; 117 AA.
AC	Q9EOX0; Q9MUZ1;		
DT	28-FEB-2003	(Rel. 41, Created)	
DT	28-FEB-2003	(Rel. 41, Last sequence update)	
DT	13-SEP-2005	(Rel. 48, Last annotation update)	
DE	Ghr1in precursor (growth hormone secretagogue) (growth hormone		
DE	releasing peptide) (Motilin-related peptide) (M46 protein).		
GN	Name=Ghr1; Synonyms=Mt1p;		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;		
OC	Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		
RN	[1]		
RP	NUCLEOTIDE SEQUENCE [MRNA] (ISOPFORMS 1 AND 2), PROTEIN SEQUENCE OF		
RP	24-30, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.		
RC	TISSUE=Stomach;		
RX	MEDLINE=20389976; PubMed=10930375;		
RX	Tomasetto C., Karam S.M., Ribieras S., Masson R., Lefebvre O.,		
RA	Staub A., Alexander G., Chénard M.-P., Rio M.-C.;		
RT	"Identification and characterization of a novel gastric peptide		
RT	hormone: the motilin-related peptide.";		
RL	Gastroenterology 119:395-405(2000).		

[2]
 NP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
 RA Kojima M.;
 RT "Mouse mRNA for preproghrelin.";
 RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.
 RN [3]
 NP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
 RA Tanaka M., Hayashida Y., Iguchi T., Nakao N., Nakai N., Nakashima K.;
 RL Submitted (Apr-2001) to the EMBL/GenBank/DBJ databases.
 RN [4]
 NP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
 RC STRAIN=C57BL/6J; TISSUE=Stomach;
 RX MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;
 RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,
 RA Nishida I., Oeato N., Saito R., Suzuki H., Yamataka I., Kiyosawa H.,
 RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,
 RA Balderelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.W.,
 RA Schmitt L.M., Knapman A., Matsuda H., Batalov S., Beisel K.M.,
 RA Blake J.A., Brad D., Brusic V., Chochia C., Corbani L.E., Cousins S.,
 RA Dalia E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,
 RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,
 RA Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,
 RA Kanai A., Kawaji H., Kawasawa Y., Kedierski R.M., King B.L.,
 RA Kongaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons P.A.,
 RA Maglott D.R., Maltsev L., Marchionni L., McKenzie L., Miki H.,
 RA Nagashima T., Nunata K., Okido T., Pavan W.D., Petrea G., Pesole G.,
 RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramachandran S.,
 RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,
 RA Sandelin A., Schneider C., Sempke C.A., Setou M., Shimada K.,
 RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,
 RA Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,
 RA Wilmshing L.G., Wymshaw-Boris A., Yamagisawa M., Yang I., Yang L.,
 RA Yuan Z., Zavoian M., Zhu Y., Zimmer A., Carlini P., Hayatsu N.,
 RA Hironaka-Kishikawa T., Kono H., Nakamura N., Sakazume N., Sato K.,
 RA Shiraki T., Maki K., Kawai J., Aizawa K., Arikawa T., Fukuda S.,
 RA Hara A., Hoshizune W., Imorani K., Ishii Y., Itoh M., Kagawa I.,
 RA Miyazaki A., Sakai K., Sasaki D., Shibata K., Shingawa A.,
 RA Yasunishi A., Yoshino K., Sasaki D., Shibata K., Shingawa A.,
 RA Birney E., Hayashizaki Y.;
 RT "Analysis of the mouse transcriptome based on functional annotation of
 60,770 full-length cDNAs.";
 RL Nature 420:563-573 (2002).
 RN [5]
 NP DEVELOPMENTAL STAGE, AND ACYLATION OF SER-26.
 RX PubMed=15746259; DOI=10.1210/en.2004-0645;
 RA Nishi Y., Higuchi H., Mifune H., Sato T., Kangawa K., Kojima M.;
 RT "Developmental changes in the pattern of ghrelin's acyl modification
 and the levels of acyl-modified ghrelin in murine stomach.";
 RL Endocrinology 146:2709-2715(2005).
 RN [6]
 NP REVIEW.
 RX MEDLINE=21203998; PubMed=11306336; DOI=10.1016/S1043-2760(00)00362-3;
 RA Kojima M., Hosoda H., Matsuo H., Kangawa K.;
 RT Ghrelin: discovery of the natural endogenous ligand for the growth
 hormone secretagogue receptor.";
 RL Trends Endocrinol. Metab. 12:118-122(2001).
 CC -1- FUNCTION: Specific ligand for the growth hormone secretagogue
 receptor type 1 (GHSR) inducing the release of growth hormone from
 the pituitary. Has an appetite-stimulating effect, induces
 adiposity and stimulates gastric acid secretion. Involved in
 growth regulation.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=1; Synonyms=Chrlin;
 CC Name=2; Synonyms=del-Gln14-ghrelin;
 CC Name=3; Synonyms=del-Gln14-ghrelin;
 CC Name=4; Synonyms=del-Gln14-ghrelin;
 CC Name=5; Synonyms=del-Gln14-ghrelin;
 CC Name=6; Synonyms=del-Gln14-ghrelin;
 CC Name=7; Synonyms=del-Gln14-ghrelin;
 CC Name=8; Synonyms=del-Gln14-ghrelin;
 CC Name=9; Synonyms=del-Gln14-ghrelin;
 CC Name=10; Synonyms=del-Gln14-ghrelin;
 CC Name=11; Synonyms=del-Gln14-ghrelin;
 CC Name=12; Synonyms=del-Gln14-ghrelin;
 CC Name=13; Synonyms=del-Gln14-ghrelin;
 CC Name=14; Synonyms=del-Gln14-ghrelin;
 CC Name=15; Synonyms=del-Gln14-ghrelin;
 CC Name=16; Synonyms=del-Gln14-ghrelin;
 CC Name=17; Synonyms=del-Gln14-ghrelin;
 CC Name=18; Synonyms=del-Gln14-ghrelin;
 CC Name=19; Synonyms=del-Gln14-ghrelin;
 CC Name=20; Synonyms=del-Gln14-ghrelin;
 CC Name=21; Synonyms=del-Gln14-ghrelin;
 CC Name=22; Synonyms=del-Gln14-ghrelin;
 CC Name=23; Synonyms=del-Gln14-ghrelin;
 CC Name=24; Synonyms=del-Gln14-ghrelin;
 CC Name=25; Synonyms=del-Gln14-ghrelin;
 CC Name=26; Synonyms=del-Gln14-ghrelin;
 CC Name=27; Synonyms=del-Gln14-ghrelin;
 CC Name=28; Synonyms=del-Gln14-ghrelin;
 CC Name=29; Synonyms=del-Gln14-ghrelin;
 CC Name=30; Synonyms=del-Gln14-ghrelin;
 CC Name=31; Synonyms=del-Gln14-ghrelin;
 CC Name=32; Synonyms=del-Gln14-ghrelin;
 CC Name=33; Synonyms=del-Gln14-ghrelin;
 CC Name=34; Synonyms=del-Gln14-ghrelin;
 CC Name=35; Synonyms=del-Gln14-ghrelin;
 CC Name=36; Synonyms=del-Gln14-ghrelin;
 CC Name=37; Synonyms=del-Gln14-ghrelin;
 CC Name=38; Synonyms=del-Gln14-ghrelin;
 CC Name=39; Synonyms=del-Gln14-ghrelin;
 CC Name=40; Synonyms=del-Gln14-ghrelin;
 CC Name=41; Synonyms=del-Gln14-ghrelin;
 CC Name=42; Synonyms=del-Gln14-ghrelin;
 CC Name=43; Synonyms=del-Gln14-ghrelin;
 CC Name=44; Synonyms=del-Gln14-ghrelin;
 CC Name=45; Synonyms=del-Gln14-ghrelin;
 CC Name=46; Synonyms=del-Gln14-ghrelin;
 CC Name=47; Synonyms=del-Gln14-ghrelin;
 CC Name=48; Synonyms=del-Gln14-ghrelin;
 CC Name=49; Synonyms=del-Gln14-ghrelin;
 CC Name=50; Synonyms=del-Gln14-ghrelin;
 CC Name=51; Synonyms=del-Gln14-ghrelin;
 CC Name=52; Synonyms=del-Gln14-ghrelin;
 CC Name=53; Synonyms=del-Gln14-ghrelin;
 CC Name=54; Synonyms=del-Gln14-ghrelin;
 CC Name=55; Synonyms=del-Gln14-ghrelin;
 CC Name=56; Synonyms=del-Gln14-ghrelin;
 CC Name=57; Synonyms=del-Gln14-ghrelin;
 CC Name=58; Synonyms=del-Gln14-ghrelin;
 CC Name=59; Synonyms=del-Gln14-ghrelin;
 CC Name=60; Synonyms=del-Gln14-ghrelin;
 CC Name=61; Synonyms=del-Gln14-ghrelin;
 CC Name=62; Synonyms=del-Gln14-ghrelin;
 CC Name=63; Synonyms=del-Gln14-ghrelin;
 CC Name=64; Synonyms=del-Gln14-ghrelin;
 CC Name=65; Synonyms=del-Gln14-ghrelin;
 CC Name=66; Synonyms=del-Gln14-ghrelin;
 CC Name=67; Synonyms=del-Gln14-ghrelin;
 CC Name=68; Synonyms=del-Gln14-ghrelin;
 CC Name=69; Synonyms=del-Gln14-ghrelin;
 CC Name=70; Synonyms=del-Gln14-ghrelin;
 CC Name=71; Synonyms=del-Gln14-ghrelin;
 CC Name=72; Synonyms=del-Gln14-ghrelin;
 CC Name=73; Synonyms=del-Gln14-ghrelin;
 CC Name=74; Synonyms=del-Gln14-ghrelin;
 CC Name=75; Synonyms=del-Gln14-ghrelin;
 CC Name=76; Synonyms=del-Gln14-ghrelin;
 CC Name=77; Synonyms=del-Gln14-ghrelin;
 CC Name=78; Synonyms=del-Gln14-ghrelin;
 CC Name=79; Synonyms=del-Gln14-ghrelin;
 CC Name=80; Synonyms=del-Gln14-ghrelin;
 CC Name=81; Synonyms=del-Gln14-ghrelin;
 CC Name=82; Synonyms=del-Gln14-ghrelin;
 CC Name=83; Synonyms=del-Gln14-ghrelin;
 CC Name=84; Synonyms=del-Gln14-ghrelin;
 CC Name=85; Synonyms=del-Gln14-ghrelin;
 CC Name=86; Synonyms=del-Gln14-ghrelin;
 CC Name=87; Synonyms=del-Gln14-ghrelin;
 CC Name=88; Synonyms=del-Gln14-ghrelin;
 CC Name=89; Synonyms=del-Gln14-ghrelin;
 CC Name=90; Synonyms=del-Gln14-ghrelin;
 CC Name=91; Synonyms=del-Gln14-ghrelin;
 CC Name=92; Synonyms=del-Gln14-ghrelin;
 CC Name=93; Synonyms=del-Gln14-ghrelin;
 CC Name=94; Synonyms=del-Gln14-ghrelin;
 CC Name=95; Synonyms=del-Gln14-ghrelin;
 CC Name=96; Synonyms=del-Gln14-ghrelin;
 CC Name=97; Synonyms=del-Gln14-ghrelin;
 CC Name=98; Synonyms=del-Gln14-ghrelin;
 CC Name=99; Synonyms=del-Gln14-ghrelin;
 CC Name=100; Synonyms=del-Gln14-ghrelin;
 CC Name=101; Synonyms=del-Gln14-ghrelin;
 CC Name=102; Synonyms=del-Gln14-ghrelin;
 CC Name=103; Synonyms=del-Gln14-ghrelin;
 CC Name=104; Synonyms=del-Gln14-ghrelin;
 CC Name=105; Synonyms=del-Gln14-ghrelin;
 CC Name=106; Synonyms=del-Gln14-ghrelin;
 CC Name=107; Synonyms=del-Gln14-ghrelin;
 CC Name=108; Synonyms=del-Gln14-ghrelin;
 CC Name=109; Synonyms=del-Gln14-ghrelin;
 CC Name=110; Synonyms=del-Gln14-ghrelin;
 CC Name=111; Synonyms=del-Gln14-ghrelin;
 CC Name=112; Synonyms=del-Gln14-ghrelin;
 CC Name=113; Synonyms=del-Gln14-ghrelin;
 CC Name=114; Synonyms=del-Gln14-ghrelin;
 CC Name=115; Synonyms=del-Gln14-ghrelin;
 CC Name=116; Synonyms=del-Gln14-ghrelin;
 CC Name=117; Synonyms=del-Gln14-ghrelin;
 CC Name=118; Synonyms=del-Gln14-ghrelin;
 CC Name=119; Synonyms=del-Gln14-ghrelin;
 CC Name=120; Synonyms=del-Gln14-ghrelin;
 CC Name=121; Synonyms=del-Gln14-ghrelin;
 CC Name=122; Synonyms=del-Gln14-ghrelin;
 CC Name=123; Synonyms=del-Gln14-ghrelin;
 CC Name=124; Synonyms=del-Gln14-ghrelin;
 CC Name=125; Synonyms=del-Gln14-ghrelin;
 CC Name=126; Synonyms=del-Gln14-ghrelin;
 CC Name=127; Synonyms=del-Gln14-ghrelin;
 CC Name=128; Synonyms=del-Gln14-ghrelin;
 CC Name=129; Synonyms=del-Gln14-ghrelin;
 CC Name=130; Synonyms=del-Gln14-ghrelin;
 CC Name=131; Synonyms=del-Gln14-ghrelin;
 CC Name=132; Synonyms=del-Gln14-ghrelin;
 CC Name=133; Synonyms=del-Gln14-ghrelin;
 CC Name=134; Synonyms=del-Gln14-ghrelin;
 CC Name=135; Synonyms=del-Gln14-ghrelin;
 CC Name=136; Synonyms=del-Gln14-ghrelin;
 CC Name=137; Synonyms=del-Gln14-ghrelin;
 CC Name=138; Synonyms=del-Gln14-ghrelin;
 CC Name=139; Synonyms=del-Gln14-ghrelin;
 CC Name=140; Synonyms=del-Gln14-ghrelin;
 CC Name=141; Synonyms=del-Gln14-ghrelin;
 CC Name=142; Synonyms=del-Gln14-ghrelin;
 CC Name=143; Synonyms=del-Gln14-ghrelin;
 CC Name=144; Synonyms=del-Gln14-ghrelin;
 CC Name=145; Synonyms=del-Gln14-ghrelin;
 CC Name=146; Synonyms=del-Gln14-ghrelin;
 CC Name=147; Synonyms=del-Gln14-ghrelin;
 CC Name=148; Synonyms=del-Gln14-ghrelin;
 CC Name=149; Synonyms=del-Gln14-ghrelin;
 CC Name=150; Synonyms=del-Gln14-ghrelin;
 CC Name=151; Synonyms=del-Gln14-ghrelin;
 CC Name=152; Synonyms=del-Gln14-ghrelin;
 CC Name=153; Synonyms=del-Gln14-ghrelin;
 CC Name=154; Synonyms=del-Gln14-ghrelin;
 CC Name=155; Synonyms=del-Gln14-ghrelin;
 CC Name=156; Synonyms=del-Gln14-ghrelin;
 CC Name=157; Synonyms=del-Gln14-ghrelin;
 CC Name=158; Synonyms=del-Gln14-ghrelin;
 CC Name=159; Synonyms=del-Gln14-ghrelin;
 CC Name=160; Synonyms=del-Gln14-ghrelin;
 CC Name=161; Synonyms=del-Gln14-ghrelin;
 CC Name=162; Synonyms=del-Gln14-ghrelin;
 CC Name=163; Synonyms=del-Gln14-ghrelin;
 CC Name=164; Synonyms=del-Gln14-ghrelin;
 CC Name=165; Synonyms=del-Gln14-ghrelin;
 CC Name=166; Synonyms=del-Gln14-ghrelin;
 CC Name=167; Synonyms=del-Gln14-ghrelin;
 CC Name=168; Synonyms=del-Gln14-ghrelin;
 CC Name=169; Synonyms=del-Gln14-ghrelin;
 CC Name=170; Synonyms=del-Gln14-ghrelin;
 CC Name=171; Synonyms=del-Gln14-ghrelin;
 CC Name=172; Synonyms=del-Gln14-ghrelin;
 CC Name=173; Synonyms=del-Gln14-ghrelin;
 CC Name=174; Synonyms=del-Gln14-ghrelin;
 CC Name=175; Synonyms=del-Gln14-ghrelin;
 CC Name=176; Synonyms=del-Gln14-ghrelin;
 CC Name=177; Synonyms=del-Gln14-ghrelin;
 CC Name=178; Synonyms=del-Gln14-ghrelin;
 CC Name=179; Synonyms=del-Gln14-ghrelin;
 CC Name=180; Synonyms=del-Gln14-ghrelin;
 CC Name=181; Synonyms=del-Gln14-ghrelin;
 CC Name=182; Synonyms=del-Gln14-ghrelin;
 CC Name=183; Synonyms=del-Gln14-ghrelin;
 CC Name=184; Synonyms=del-Gln14-ghrelin;
 CC Name=185; Synonyms=del-Gln14-ghrelin;
 CC Name=186; Synonyms=del-Gln14-ghrelin;
 CC Name=187; Synonyms=del-Gln14-ghrelin;
 CC Name=188; Synonyms=del-Gln14-ghrelin;
 CC Name=189; Synonyms=del-Gln14-ghrelin;
 CC Name=190; Synonyms=del-Gln14-ghrelin;
 CC Name=191; Synonyms=del-Gln14-ghrelin;
 CC Name=192; Synonyms=del-Gln14-ghrelin;
 CC Name=193; Synonyms=del-Gln14-ghrelin;
 CC Name=194; Synonyms=del-Gln14-ghrelin;
 CC Name=195; Synonyms=del-Gln14-ghrelin;
 CC Name=196; Synonyms=del-Gln14-ghrelin;
 CC Name=197; Synonyms=del-Gln14-ghrelin;
 CC Name=198; Synonyms=del-Gln14-ghrelin;
 CC Name=199; Synonyms=del-Gln14-ghrelin;
 CC Name=200; Synonyms=del-Gln14-ghrelin;
 CC Name=201; Synonyms=del-Gln14-ghrelin;
 CC Name=202; Synonyms=del-Gln14-ghrelin;
 CC Name=203; Synonyms=del-Gln14-ghrelin;
 CC Name=204; Synonyms=del-Gln14-ghrelin;
 CC Name=205; Synonyms=del-Gln14-ghrelin;
 CC Name=206; Synonyms=del-Gln14-ghrelin;
 CC Name=207; Synonyms=del-Gln14-ghrelin;
 CC Name=208; Synonyms=del-Gln14-ghrelin;
 CC Name=209; Synonyms=del-Gln14-ghrelin;
 CC Name=210; Synonyms=del-Gln14-ghrelin;
 CC Name=211; Synonyms=del-Gln14-ghrelin;
 CC Name=212; Synonyms=del-Gln14-ghrelin;
 CC Name=213; Synonyms=del-Gln14-ghrelin;
 CC Name=214; Synonyms=del-Gln14-ghrelin;
 CC Name=215; Synonyms=del-Gln14-ghrelin;
 CC Name=216; Synonyms=del-Gln14-ghrelin;
 CC Name=217; Synonyms=del-Gln14-ghrelin;
 CC Name=218; Synonyms=del-Gln14-ghrelin;
 CC Name=219; Synonyms=del-Gln14-ghrelin;
 CC Name=220; Synonyms=del-Gln14-ghrelin;
 CC Name=221; Synonyms=del-Gln14-ghrelin;
 CC Name=222; Synonyms=del-Gln14-ghrelin;
 CC Name=223; Synonyms=del-Gln14-ghrelin;
 CC Name=224; Synonyms=del-Gln14-ghrelin;
 CC Name=225; Synonyms=del-Gln14-ghrelin;
 CC Name=226; Synonyms=del-Gln14-ghrelin;
 CC Name=227; Synonyms=del-Gln14-ghrelin;
 CC Name=228; Synonyms=del-Gln14-ghrelin;
 CC Name=229; Synonyms=del-Gln14-ghrelin;
 CC Name=230; Synonyms=del-Gln14-ghrelin;
 CC Name=231; Synonyms=del-Gln14-ghrelin;
 CC Name=232; Synonyms=del-Gln14-ghrelin;
 CC Name=233; Synonyms=del-Gln14-ghrelin;
 CC Name=234; Synonyms=del-Gln14-ghrelin;
 CC Name=235; Synonyms=del-Gln14-ghrelin;
 CC Name=236; Synonyms=del-Gln14-ghrelin;
 CC Name=237; Synonyms=del-Gln14-ghrelin;
 CC Name=238; Synonyms=del-Gln14-ghrelin;
 CC Name=239; Synonyms=del-Gln14-ghrelin;
 CC Name=240; Synonyms=del-Gln14-ghrelin;
 CC Name=241; Synonyms=del-Gln14-ghrelin;
 CC Name=242; Synonyms=del-Gln14-ghrelin;
 CC Name=243; Synonyms=del-Gln14-ghrelin;
 CC Name=244; Synonyms=del-Gln14-ghrelin;
 CC Name=245; Synonyms=del-Gln14-ghrelin;
 CC Name=246; Synonyms=del-Gln14-ghrelin;
 CC Name=247; Synonyms=del-Gln14-ghrelin;
 CC Name=248; Synonyms=del-Gln14-ghrelin;
 CC Name=249; Synonyms=del-Gln14-ghrelin;
 CC Name=250; Synonyms=del-Gln14-ghrelin;
 CC Name=251; Synonyms=del-Gln14-ghrelin;
 CC Name=252; Synonyms=del-Gln14-ghrelin;
 CC Name=253; Synonyms=del-Gln14-ghrelin;
 CC Name=254; Synonyms=del-Gln14-ghrelin;
 CC Name=255; Synonyms=del-Gln14-ghrelin;
 CC Name=256; Synonyms=del-Gln14-ghrelin;
 CC Name=257; Synonyms=del-Gln14-ghrelin;
 CC Name=258; Synonyms=del-Gln14-ghrelin;
 CC Name=259; Synonyms=del-Gln14-ghrelin;
 CC Name=260; Synonyms=del-Gln14-ghrelin;
 CC Name=261; Synonyms=del-Gln14-ghrelin;
 CC Name=262; Synonyms=del-Gln14-ghrelin;
 CC Name=263; Synonyms=del-Gln14-ghrelin;
 CC Name=264; Synonyms=del-Gln14-ghrelin;
 CC Name=265; Synonyms=del-Gln14-ghrelin;
 CC Name=266; Synonyms=del-Gln14-ghrelin;
 CC Name=267; Synonyms=del-Gln14-ghrelin;
 CC Name=268; Synonyms=del-Gln14-ghrelin;
 CC Name=269; Synonyms=del-Gln14-ghrelin;
 CC Name=270; Synonyms=del-Gln14-ghrelin;
 CC Name=271; Synonyms=del-Gln14-ghrelin;
 CC Name=272; Synonyms=del-Gln14-ghrelin;
 CC Name=273; Synonyms=del-Gln14-ghrelin;
 CC Name=274; Synonyms=del-Gln14-ghrelin;
 CC Name=275; Synonyms=del-Gln14-ghrelin;
 CC Name=276; Synonyms=del-Gln14-ghrelin;
 CC Name=277; Synonyms=del-Gln14-ghrelin;
 CC Name=278; Synonyms=del-Gln14-ghrelin;
 CC Name=279; Synonyms=del-Gln14-ghrelin;
 CC Name=280; Synonyms=del-Gln14-ghrelin;
 CC Name=281; Synonyms=del-Gln14-ghrelin;
 CC Name=282; Synonyms=del-Gln14-ghrelin;
 CC Name=283; Synonyms=del-Gln14-ghrelin;
 CC Name=284; Synonyms=del-Gln14-ghrelin;
 CC Name=285; Synonyms=del-Gln14-ghrelin;
 CC Name=286; Synonyms=del-Gln14-ghrelin;
 CC Name=287; Synonyms=del-Gln14-ghrelin;
 CC Name=288; Synonyms=del-Gln14-ghrelin;
 CC Name=289; Synonyms=del-Gln14-ghrelin;
 CC Name=290; Synonyms=del-Gln14-ghrelin;
 CC Name=291; Synonyms=del-Gln14-ghrelin;
 CC Name=292; Synonyms=del-Gln14-ghrelin;
 CC Name=293; Synonyms=del-Gln14-ghrelin;
 CC Name=294; Synonyms=del-Gln14-ghrelin;
 CC Name=295; Synonyms=del-Gln14-ghrelin;
 CC Name=296; Synonyms=del-Gln14-ghrelin;
 CC Name=297; Synonyms=del-Gln14-ghrelin;
 CC Name=298; Synonyms=del-Gln14-ghrelin;
 CC Name=299; Synonyms=del-Gln14-ghrelin;
 CC Name=300; Synonyms=del-Gln14-ghrelin;
 CC Name=301; Synonyms=del-Gln14-ghrelin;
 CC Name=302; Synonyms=del-Gln14-ghrelin;
 CC Name=303; Synonyms=del-Gln14-ghrelin;
 CC Name=304; Synonyms=del-Gln14-ghrelin;
 CC Name=305; Synonyms=del-Gln14-ghrelin;
 CC Name=306; Synonyms=del-Gln14-ghrelin;
 CC Name=307; Synonyms=del-Gln14-ghrelin;
 CC Name=308; Synonyms=del-Gln14-ghrelin;
 CC Name=309; Synonyms=del-Gln14-ghrelin;
 CC Name=310; Synonyms=del-Gln14-ghrelin;
 CC Name=311; Synonyms=del-Gln14-ghrelin;
 CC Name=312; Synonyms=del-Gln14-ghrelin;
 CC Name=313; Synonyms=del-Gln14-ghrelin;
 CC Name=314; Synonyms=del-Gln14-ghrelin;
 CC Name=315; Synonyms=del-Gln14-ghrelin;
 CC Name=316; Synonyms=del-Gln14-ghrelin;
 CC Name=317; Synonyms=del-Gln14-ghrelin;
 CC Name=318; Synonyms=del-Gln14-ghrelin;
 CC Name=319; Synonyms=del-Gln14-ghrelin;
 CC Name=320; Synonyms=del-Gln14-ghrelin;
 CC Name=321; Synonyms=del-Gln14-ghrelin;
 CC Name=322; Synonyms=del-Gln14-ghrelin;
 CC Name=323; Synonyms=del-Gln14-ghrelin;
 CC Name=324; Synonyms=del-Gln14-ghrelin;
 CC Name=325; Synonyms=del-Gln14-ghrelin;
 CC Name=326; Synonyms=del-Gln14-ghrelin;
 CC Name=327; Synonyms=del-Gln14-ghrelin;
 CC Name=328; Synonyms=del-Gln14-ghrelin;
 CC Name=329; Synonyms=del-Gln14-ghrelin;
 CC Name=330; Synonyms=del-Gln14-ghrelin;
 CC Name=331; Synonyms=del-Gln14-ghrelin;
 CC Name=332; Synonyms=del-Gln14-ghrelin;
 CC Name=333; Synonyms=del-Gln14-ghrelin;
 CC Name=334; Synonyms=del-Gln14-ghrelin;
 CC Name=335; Synonyms=del-Gln14-ghrelin;
 CC Name=336; Synonyms=del-Gln14-ghrelin;
 CC Name=337; Synonyms=del-Gln14-ghrelin;
 CC Name=338; Synonyms=del-Gln14-ghrelin;
 CC Name=339; Synonyms=del-Gln14-ghrelin;
 CC Name=340; Synonyms=del-Gln14-ghrelin;
 CC Name=341; Synonyms=del-Gln14-ghrelin;
 CC Name=342; Synonyms=del-Gln14-ghrelin;
 CC Name=343; Synonyms=del-Gln14-ghrelin;
 CC Name=344; Synonyms=del-Gln14-ghrelin;
 CC Name=345; Synonyms=del-Gln14-ghrelin;
 CC Name=346; Synonyms=del-Gln14-ghrelin;
 CC Name=347; Synonyms=del-Gln14-ghrelin;
 CC Name=348; Synonyms=del-Gln14-ghrelin;
 CC Name=349; Synonyms=del-Gln14-ghrelin;
 CC Name=350; Synonyms=del-Gln14-ghrelin;
 CC Name=351; Synonyms=del-Gln14-ghrelin;
 CC Name=352; Synonyms=del-Gln14-ghrelin;
 CC Name=353; Synonyms=del-Gln14-ghrelin;
 CC Name=354; Synonyms=del-Gln14-ghrelin;
 CC Name=355; Synonyms=del-Gln14-ghrelin;
 CC Name=356; Synonyms=del-Gln14-ghrelin;
 CC Name=357; Synonyms=del-Gln14-ghrelin;
 CC Name=358; Synonyms=del-Gln14-ghrelin;
 CC Name=359; Synonyms=del-Gln14-ghrelin;
 CC Name=360; Synonyms=del-Gln14-ghrelin;
 CC Name=361; Synonyms=del-Gln14-ghrelin;
 CC Name=362; Synonyms=del-Gln14-ghrelin;
 CC Name=363; Synonyms=del-Gln14-ghrelin;
 CC Name=364; Synonyms=del-Gln14-ghrelin;
 CC Name=365; Synonyms=del-Gln14-ghrelin;
 CC Name=366; Synonyms=del-Gln14-ghrelin;
 CC Name=367; Synonyms=del-Gln14-ghrelin;
 CC Name=368; Synonyms=del-Gln14-ghrelin;
 CC Name=369; Synonyms=del-Gln14-ghrelin;
 CC Name=370; Synonyms=del-Gln14-ghrelin;
 CC Name=371; Synonyms=del-Gln14-ghrelin;
 CC Name=372; Synonyms=del-Gln14-ghrelin;
 CC Name=373; Synonyms=del-Gln14-ghrelin;
 CC Name=374; Synonyms=del-Gln14-ghrelin;
 CC Name=375; Synonyms=del-Gln14-ghrelin;
 CC Name=376; Synonyms=del-Gln14-ghrelin;
 CC Name=377; Synonyms=del-Gln14-ghrelin;
 CC Name=378; Synonyms=del-Gln14-ghrelin;
 CC Name=379; Synonyms=del-Gln14-ghrelin;
 CC Name=380; Synonyms=del-Gln14-ghrelin;
 CC Name=381; Synonyms=del-Gln14-ghrelin;
 CC Name=382; Synonyms=del-Gln14-ghrelin;
 CC Name=383; Synonyms=del-Gln14-ghrelin;
 CC Name=384; Synonyms=del-Gln14-ghrelin;
 CC Name=385; Synonyms=del-Gln14-ghrelin;
 CC Name=386; Synonyms=del-Gln14-ghrelin;
 CC Name=387; Synonyms=del-Gln14-ghrelin;
 CC Name=388; Synonyms=del-Gln14-ghrelin;
 CC Name=389; Synonyms=del-Gln14-ghrelin;
 CC Name=390; Synonyms=del-Gln14-ghrelin;
 CC Name=391; Synonyms=del-Gln14-ghrelin;
 CC Name=392; Synonyms=del-Gln14-ghrelin;
 CC Name=393; Synonyms=del-Gln14-ghrelin;
 CC Name=394; Synonyms=del-Gln14-ghrelin;
 CC Name=395; Synonyms=del-Gln14-ghrelin;
 CC Name=396; Synonyms=del-Gln14-ghrelin;
 CC Name=397; Synonyms=del-Gln14-ghrelin;
 CC Name=398; Synonyms=del-Gln14-ghrelin;
 CC Name=399; Synonyms=del-Gln14-ghrelin;
 CC Name=400; Synonyms=del-Gln14-ghrelin;
 CC Name=401; Synonyms=del-Gln14-ghrelin;
 CC Name=402; Synonyms=del-Gln14-ghrelin;
 CC Name=403; Synonyms=del-Gln14-ghrelin;
 CC Name=404; Synonyms=del-Gln14-ghrelin;
 CC Name=405; Synonyms=del-Gln14-ghrelin;
 CC Name=406; Synonyms=del-Gln14-ghrelin;
 CC Name=407; Synonyms=del-Gln14-ghrelin;
 CC Name=408; Synonyms=del-Gln14-ghrelin;
 CC Name=409; Synonyms=del-Gln14-ghrelin;
 CC Name=410; Synonyms=del-Gln14-ghrelin;
 CC Name=411; Synonyms=del-Gln14-ghrelin;
 CC Name=412; Synonyms=del-Gln14-ghrelin;
 CC Name=413; Synonyms=del-Gln14-ghrelin;
 CC Name=414; Synonyms=del-Gln14-ghrelin;
 CC Name=415; Synonyms=del-Gln14-ghrelin;
 CC Name=416; Synonyms=del-Gln14-ghrelin;
 CC Name=417; Synonyms=del-Gln14-ghrelin;
 CC Name=418; Synonyms=del-Gln14-ghrelin;
 CC Name=419; Synonyms=del-Gln14-ghrelin;
 CC Name=420; Synonyms=del-Gln14-ghrelin;
 CC Name=421; Synonyms=del-Gln14-ghrelin;
 CC Name=422; Synonyms=del-Gln14-ghrelin;
 CC Name=423; Synonyms=del-Gln14-ghrelin;
 CC Name=424; Synonyms=del-Gln14-ghrelin;
 CC Name=425; Synonyms=del-Gln14-ghrelin;
 CC Name=426; Synonyms=del-Gln14-ghrelin;
 CC Name=427; Synonyms=del-Gln14-ghrelin;
 CC Name=428; Synonyms=del-Gln14-ghrelin;
 CC Name=429; Synonyms=del-Gln14-ghrelin;
 CC Name=430; Synonyms=del-Gln14-ghrelin;
 CC Name=431; Synonyms=del-Gln14-ghrelin;
 CC Name=432; Synonyms=del-Gln14-ghrelin;
 CC Name=433; Synonyms=del-Gln14-ghrelin;
 CC Name=434; Synonyms=del-Gln14-ghrelin;
 CC Name=435; Synonyms=del-Gln14-ghrelin;
 CC Name=436; Synonyms=del-Gln14-ghrelin;
 CC Name=437; Synonyms=del-Gln14-ghrelin;
 CC Name=438; Synonyms=del-Gln14-ghrelin;
 CC Name=439; Synonyms=del-Gln14-ghrelin;
 CC Name=440; Synonyms=del-Gln14-ghrelin;
 CC Name=441; Synonyms=del-Gln14-ghrelin;
 CC Name=442; Synonyms=del-Gln14-ghrelin;
 CC Name=443; Synonyms=del-Gln14-ghrelin;
 CC Name=444; Synonyms=del-Gln14-ghrelin;
 CC Name=445; Synonyms=del-Gln14-ghrelin;
 CC Name=446; Synonyms=del-Gln14-ghrelin;
 CC Name=447; Synonyms=del-Gln14-ghrelin;
 CC Name=448; Synonyms=del-Gln14-ghrelin;
 CC Name=449; Synonyms=del-Gln14-ghrelin;
 CC Name=450; Synonyms=

RA Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., Kangawa K.;
 RT "Ghrelin is a growth-hormone-releasing acylated peptide from
 RL stomach.";
 RL Nature 402:656-660(1999).
 RN [2]
 RP NUCLEOTIDE SEQUENCE [mRNA] (ISOFORMS 1 AND 2), PROTEIN SEQUENCE OF
 RP 24-51, MASS SPECTROMETRY, AND ACYLATION OF SER-26.
 RC STRAIN=Sprague-Dawley; TISSUE=Stomach;
 RX MEDLINE=20357315; PubMed=10801861; DOI=10.1074/jbc.M002784200;
 RA Hosoda H., Kojima M., Matsuo H., Kangawa K.;
 RT "Purification and characterization of rat des-Gln14-ghrelin, a second
 RT endogenous ligand for the growth hormone secretagogue receptor.";
 RL J. Biol. Chem. 275:21995-22000(2000).
 RN [3]
 RN CHARACTERIZATION.
 RX MEDLINE=21092536; PubMed=1162448; DOI=10.1006/dbrc.2000.4039;
 RA Hosoda H., Kojima M., Matsuo H., Kangawa K.;
 RT "Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide
 RT in gastrointestinal tissue.";
 RL Biochem. Biophys. Res. Commun. 279:909-913(2000).
 RN [4]
 RN STRUCTURE-ACTIVITY RELATIONSHIP.
 RX MEDLINE=21433488; PubMed=11549267; DOI=10.1006/dbrc.2001.5553;
 RA Matsuno M., Hosoda H., Kitajima Y., Morozumi N., Minamitake Y.,
 RA Tanaka S., Matsuo H., Kojima M., Hayashi Y., Kangawa K.;
 RT "Structure-activity relationship of ghrelin: pharmacological study of
 RT ghrelin peptides.";
 RL Biochem. Biophys. Res. Commun. 287:142-146(2001).
 RN [5]
 RP REVIEW.
 RX MEDLINE=21203998; PubMed=11306336; DOI=10.1016/S1043-2760(00)00362-3;
 RA Kojima M., Hosoda H., Matsuo H., Kangawa K.;
 RT "Ghrelin: discovery of the natural endogenous ligand for the growth
 RT hormone secretagogue receptor.";
 RL Trends Endocrinol. Metab. 12:118-122(2001).
 CC -1- FUNCTION: Specific ligand for the growth hormone secretagogue
 CC receptor type 1 (GHSR) inducing the release of growth hormone from
 CC the pituitary. Has an appetite-stimulating effect, induces
 CC adiposity and stimulates gastric acid secretion. Involved in
 CC growth regulation.
 CC -1- SUBCELLULAR LOCATION: Secreted.
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event=Alternative splicing; Named isoforms=2;
 CC Name=1; Synonyms=Ghrelin;
 CC IsoId=Q9QYH7-1; Sequence=DiepIay;
 CC Name=2; Synonyms=des-Gln14-ghrelin;
 CC IsoId=Q9QYH7-2; Sequence=VSP_003248;
 CC -1- TISSUE SPECIFICITY: Broadly expressed with higher expression in
 CC the stomach. Very low levels are detected in the hypothalamus,
 CC heart, lung, pancreas, intestine and adipose tissue.
 CC -1- PTM: O-n-octanoylation is essential for activity. The replacement
 CC of Ser-26 by aromatic tryptophan preserves ghrelin activity.
 CC -1- MASS SPECTROMETRY: MW=3314.9; MW ERR=0.7; METHOD=Electrospray;
 CC RANGE=24-51 (Q9QYH7-1); NOTE=Ref.1.
 CC -1- MASS SPECTROMETRY: MW=3187.1; MW ERR=0.6; METHOD=Electrospray;
 CC RANGE=24-50 (Q9QYH7-2); NOTE=Ref.2.
 CC -1- SIMILARITY: Belongs to the motilin family.
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.

DR GO; GO:0050791; P:regulation of physiological process; NAS.
 DR InterPro; IPR006737; motilin_assoc.
 DR InterPro; IPR006738; motilin_ghrelin.
 DR InterPro; IPR005441; Preproghrelin.
 DR PANTHER; PTHR14122; Preproghrelin; 1.
 DR Pfam; PF04643; Motilin_assoc; 1.
 DR Pfam; PF04644; Motilin_ghrelin; 1.
 DR PRINTS; PR01624; GHRELIN.
 DR ProDom; PD332162; Preproghrelin; 1.
 KW Alternative splicing; Direct protein sequencing; Hormone; Lipoprotein;
 KW Signal.
 FT SIGNAL. 1 23
 FT PEPTIDE 24 51 Ghrelin.
 FT PROPEP 52 117 Removed in mature form.
 FT LIPID 26 26 O-octanoyl serine.
 FT VARSPLIC 37 37 Missing (in isoform 2).
 FT FT
 SQ SEQUENCE 117 AA; 13176 MW; 8857546F51A7691 CRC64;

Query Match 95.2%; Score 138; DB 1; Length 117;
 Best Local Similarity 92.9%; Pred. No. 1.2e-10;
 Matches 26; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 1 GSSFLSPBHQVQQRKSKKPPATLQPR 28
 |||||
 Db 24 GSSFLSPBHQVQQRKSKKPPATLQPR 51

RESULT 9
 ID Q8CH53_MERUN PRELIMINARY; PRT; 117 AA.
 AC Q8CH53;
 DT 01-MAR-2003 (TRENDBLREL. 23, Created)
 DT 01-MAR-2003 (TRENDBLREL. 23, Last sequence update)
 DT 01-JUN-2003 (TRENDBLREL. 24, Last annotation update)
 DE Ghrelin preproprotein.
 OS Meriones unguiculatus (Mongolian jird) (Mongolian gerbil).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridae; Gerbillinae; Meriones.
 NCBI_TaxID=10047;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RX PubMed=14724148; DOI=10.1136/gut.2003.021568;
 RA Suzuki K., Maseoka T., Hosoda H., Oca T., Minegishi Y., Nomura S.,
 RA Kangawa K., Ishii H.;
 RT "Helicobacter pylori infection modifies gastric and plasma ghrelin
 RT dynamics in Mongolian gerbils.";
 RL Gut 53:187-194(2004).
 DR EMBL; AF442491; AAC06965.1; -; mRNA.
 DR GO; GO:0005576; C:extracellular region; IEA.
 DR GO; GO:0016608; F:growth hormone-releasing hormone activity; IEA.
 DR GO; GO:0050791; P:regulation of physiological process; IEA.
 DR InterPro; IPR006737; motilin_assoc.
 DR InterPro; IPR006738; Preproghrelin.
 DR PANTHER; PTHR14122; Preproghrelin; 1.
 DR Pfam; PF04643; Motilin_assoc; 1.
 DR Pfam; PF04644; Motilin_ghrelin; 1.
 DR PRINTS; PR01624; GHRELIN.
 DR ProDom; PD332162; Preproghrelin; 1.
 SQ SEQUENCE 117 AA; 13035 MW; 27657687FC026A74 CRC64;

Query Match 95.2%; Score 138; DB 2; Length 117;
 Best Local Similarity 92.9%; Pred. No. 1.2e-10;
 Matches 26; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 1 GSSFLSPBHQVQQRKSKKPPATLQPR 28
 |||||
 Db 24 GSSFLSPBHQVQQRKSKKPPATLQPR 51

RESULT 10

ID	Q6TGF0_PIG	PRELIMINARY;	PRT;	65 AA.
AC	Q6TGF0_PIG	PRELIMINARY;	PRT;	65 AA.
DT	05-JUL-2004 (TREMBLrel. 27, Created)			
DT	05-JUL-2004 (TREMBLrel. 27, Last sequence update)			
DT	05-JUL-2004 (TREMBLrel. 27, Last annotation update)			
DE	Chrelin (Fragment).			
OS	Sue scrofa (Pig).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;			
OC	Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;			
OC	Sub.			
OX	NCBI_TaxID=9823;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RA	Liu D., Zhang Y., Zhang X., Yang G.;			
RL	Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.			
DR	EMBL; AY424043; AA097622.1; -; Genomic DNA.			
DR	GO; GO:0005576; C:extracellular region; IEA.			
DR	GO; GO:0016608; F:growth hormone-releasing hormone activity; IEA.			
DR	GO; GO:0050791; F:regulation of physiological process; IEA.			
DR	InterPro; IPR0056738; molilin_ghrelin.			
DR	InterPro; IPR005441; Preproghrelin.			
DR	PANTHER; PTHR14122; Preproghrelin; 1.			
DR	Pfam; PF04644; Molilin_ghrelin; 1.			
DR	PRINTS; PR01624; GHRELIN.			
FT	NON_TER	1		
FT	NON_TER	65		
SQ	SEQUENCE	65 AA; 6979 MW; 55D3713C50144AD5 CRC64;		
Query Match 89.7%; Score 130; DB 2; Length 65;				
Best Local Similarity 89.3%; Pred. No. 7.4e-10;				
Matches 25; Conservative 2; Mismatches 1; Indels 0; Gaps 0;				
Oy	1 GSSFSPHQVQQRKSKPKAKQPR 28			
Db	22 GSSFSPHQVQQRKSKPKAKQPR 49			
RESULT 11				
ID	Q67BBS_PIG	PRELIMINARY;	PRT;	74 AA.
AC	Q67BBS_PIG	PRELIMINARY;	PRT;	74 AA.
DT	25-OCT-2004 (TREMBLrel. 28, Created)			
DT	25-OCT-2004 (TREMBLrel. 28, Last sequence update)			
DT	25-OCT-2004 (TREMBLrel. 28, Last annotation update)			
DE	Ghrelin (Fragment).			
OS	Sue scrofa (Pig).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;			
OC	Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;			
OC	Sub.			
OX	NCBI_TaxID=9823;			
RN	[1]			
RP	NUCLEOTIDE SEQUENCE.			
RA	Kim K.-S., Roehschild M.F.;			
RT	"Pig Ghrelin";			
RL	Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.			
DR	EMBL; AY373019; AAR24571.1; -; Genomic DNA.			
DR	GO; GO:0005576; C:extracellular region; IEA.			
DR	GO; GO:0016608; F:growth hormone-releasing hormone activity; IEA.			
DR	GO; GO:0050791; F:regulation of physiological process; IEA.			
DR	InterPro; IPR006738; molilin_ghrelin.			
DR	InterPro; IPR005441; Preproghrelin.			
DR	PANTHER; PTHR14122; Preproghrelin; 1.			
DR	Pfam; PF04644; Molilin_ghrelin; 1.			
DR	PRINTS; PR01624; GHRELIN.			
FT	NON_TER	74		
FT	NON_TER	74		
SQ	SEQUENCE	74 AA; 7980 MW; 875424C2D41FC166 CRC64;		
Query Match 89.7%; Score 130; DB 2; Length 74;				
Best Local Similarity 89.3%; Pred. No. 8.5e-10;				
Matches 25; Conservative 2; Mismatches 1; Indels 0; Gaps 0;				
Oy	1 GSSFSPHQVQQRKSKPKAKQPR 28			

Db	25	GSFSLSPENHOKVQGRKESKKPAALTKR	52
RESULT 12			
ID	GHRL_PIG	STANDARD;	PRT; 118 AA.
AC	O9GKX5; O9BGD8; O9GKY4;		
DT	28-FEB-2003 (Rel. 41, Created)		
DT	28-FEB-2003 (Rel. 41, Last sequence update)		
DT	13-SEP-2005 (Rel. 48, Last annotation update)		
DE	ghrelin precursor (Growth hormone secretagogue) (Growth hormone releasing peptide) (Motilin-related peptide).		
GN	Name=GHRL;		
OS	Sub scrota (pig).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;		
CC	Sub.		
CC	NCBI_TaxID=9823;		
RN	[1]		
RP	NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).		
RA	Kojima M.;		
RL	Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.		
RN	[2]		
RP	NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).		
RC	TISSUE=Stomach;		
RA	Roussellet J., Lacroix D., Dubreuil P.;		
RL	Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.		
CC	-1- FUNCTION: Specific ligand for the growth hormone secretagogue receptor type 1 (GHSR) inducing the release of growth hormone from the pituitary. Has an appetite-stimulating effect, induces adiposity and stimulates gastric acid secretion. Involved in growth regulation (By similarity).		
CC	-1- SUBCELLULAR LOCATION: Secreted (By similarity).		
CC	-1- ALTERNATIVE PRODUCTS:		
CC	Event=Alternative splicing; Named isoforms=2;		
CC	Name=1; Synonym=Chrelin;		
CC	Isoid=O9GKX5-1; Sequence=Displayed;		
CC	Name=2; Synonym=del-Gln1-ghrelin;		
CC	Isoid=O9GKX5-2; Sequence=VSP_003247;		
CC	-1- PUT: O-n-octanoylation is essential for activity (By similarity).		
CC	-1- SIMILARITY: Belongs to the motilin family.		
CC	-----		
CC	This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.		
CC	-----		
DR	EMBL; AB035703; BAB19048.1; -; mRNA.		
DR	EMBL; AB035704; BAB19049.1; -; mRNA.		
DR	EMBL; AF108930; AAK19243.1; -; mRNA.		
DR	EMBL; AY028942; AAK30002.1; -; mRNA.		
DR	InterPro; IPR006737; motilin_assoc.		
DR	InterPro; IPR006738; motilin_ghrelin.		
DR	InterPro; IPR005441; Preproghrelin.		
DR	PANTHER; PTHR4122; Preproghrelin; 1.		
DR	Pfam; PF04643; Motilin_assoc; 1.		
DR	Pfam; PF04644; Motilin_ghrelin; 1.		
DR	PRINTS; PR01624; GHRELIN.		
DR	ProDom; PD32162; Preproghrelin; 1.		
KW	Alternative splicing; Hormone; Lipoprotein; Signal.		
FT	SIGNAL	1	24
FT	PEPTIDE	53	52
FT	PROPEP	25	118
FT	LIPID	27	27
FT	VARSPLIC	38	38
FT	CONFLICT	17	17
FT	FT	72	72
FT	SEQUENCE	118 AA;	12786 MM;
Query Match	89.7%	Score 130;	DB 1; Length 118;

Best Local Similarity 89.3%; Pred. No. 1.4e-09;
Matches 25; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

OY 1 GSSFLSPHQVQQRKSKPKPAKLQPR 28
DB 25 GSSFLSPHQVQQRKSKPKPAKLKPR 52

RESULT 13

06SLG5_KOGBR PRELIMINARY; PRT; 54 AA.

AC 06SLG5;

DT 05-JUL-2004 (TREMBlrel. 27, Created)

DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)

DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)

DE Ghrelin (Fragment).

OS Kogia brevipes (Pygmy sperm whale).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Cetacea;

OC Odontoceti; Physteridae; Kogia.

NCBI_TaxID=27615;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RA Dickin J.C., Thue T.D., Buchanan F.C.;

RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.

DR EMBL; AY455981; AAS67347.1; -; Genomic DNA.

DR GO; GO:0005576; C:extracellular region; IEA.

DR GO; GO:0016608; F:growth hormone-releasing hormone activity; IEA.

DR InterPro; IPR006738; molilin_ghrelin.

DR InterPro; IPR005441; Preproghrelin.

DR PANTHER; PTHR14122; Preproghrelin; 1.

DR Pfam; PF04644; Motilin_ghrelin; 1.

DR PRINTS; PR01624; GHRELIN.

FT NON_TER 1

FT NON_TER 54

FT SEQUENCE 54 AA; 5998 MW; 777E30E0F3E472E CRC64;

Query Match 70.0%; Score 101.5; DB 2; Length 54;

Best Local Similarity 71.4%; Pred. No. 4.1e-06;
Matches 20; Conservative 5; Mismatches 2; Indels 1; Gaps 1;

OY 1 GSSFLSPHQVQQRKSKPKPAKLQPR 28
DB 18 GSSFLSPHQVQQRKSKPKPAKLKPR 44

RESULT 14

06SLG7_BOVIN PRELIMINARY; PRT; 54 AA.

AC 06SLG7;

DT 05-JUL-2004 (TREMBlrel. 27, Created)

DT 05-JUL-2004 (TREMBlrel. 27, Last sequence update)

DT 05-JUL-2004 (TREMBlrel. 27, Last annotation update)

DE Ghrelin (Fragment).

OS Bos taurus (Bovine).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;

OC Pecora; Bovidae; Bovinae; Bos.

NCBI_TaxID=9913;

RN [1]

RP NUCLEOTIDE SEQUENCE.

RA PubMed:15373749; DOI=10.1111/j.1365-2052.2004.01175.x;

RA "An alternative splice site in ghrelin is missing in ruminants.";

RL Anin. Genet. 35:411-412(2004).

DR EMBL; AY455979; AAS67345.1; -; Genomic DNA.

DR GO; GO:0005576; C:extracellular region; IEA.

DR GO; GO:0016608; F:growth hormone-releasing hormone activity; IEA.

DR InterPro; IPR006738; molilin_ghrelin.

DR InterPro; IPR005441; Preproghrelin.

DR PANTHER; PTHR14122; Preproghrelin; 1.

DR Pfam; PF04644; Motilin_ghrelin; 1.

DR PRINTS; PR01624; GHRELIN.

FT NON_TER 1

FT NON_TER 54

FT SEQUENCE 54 AA; 5998 MW; 777E30E0F3E472E CRC64;

Query Match 70.0%; Score 101.5; DB 2; Length 54;
Best Local Similarity 71.4%; Pred. No. 4.1e-06;
Matches 20; Conservative 5; Mismatches 2; Indels 1; Gaps 1;

OY 1 GSSFLSPHQVQQRKSKPKPAKLQPR 28
DB 18 GSSFLSPHQVQQRKSKPKPAKLKPR 44

RESULT 15

GHRL_BOVIN STANDARD; PRT; 116 AA.

AC Q9BDJ6; Q9GKY6;

DT 28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 13-SEP-2005 (Rel. 48, Last annotation update)

DE Ghrelin precursor (Growth hormone secretagogue) (Growth hormone releasing peptide) (Motilin-related peptide).

GN Name=GHRL;

OS Bos taurus (Bovine).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;

OC Pecora; Bovidae; Bovinae; Bos.

NCBI_TaxID=9913;

RN [1]

RP NUCLEOTIDE SEQUENCE [MRNA].

RA Kita K., Harada K., Yokota H.;

RL Submitted (FEB-2001) to the EMBL/GenBank/DBJ databases.

RN [2]

RP NUCLEOTIDE SEQUENCE [MRNA] OF 24-99.

RA Kojima M.;

RL Submitted (DEC-1999) to the EMBL/GenBank/DBJ databases.

CC -!- FUNCTION: Specific ligand for the growth hormone secretagogue receptor type 1 (GHSR) inducing the release of growth hormone from the pituitary. Has an appetite-stimulating effect. Induces

adiposity and stimulates gastric acid secretion. Involved in growth regulation (By similarity).

CC -!- SUBCELLULAR LOCATION: Secreted (By similarity).

CC -!- PTM: O-n-octanoylation is essential for activity (By similarity).

CC -!- SIMILARITY: Belongs to the motilin family.

CC -----

CC This Swiss-Prot entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL Outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use as long as its content is in no way modified and this statement is not

CC removed.

CC -----

CC EMBL; AF350329; AAK18612.1; -; mRNA.

CC EMBL; AB035702; BAB19047.1; -; mRNA.

CC InterPro; IPR006737; molilin_assoc.

CC InterPro; IPR006738; molilin_ghrelin.

CC InterPro; IPR005441; Preproghrelin.

CC PANTHER; PTHR14122; Preproghrelin; 1.

CC Pfam; PF04643; Motilin_assoc; 1.

CC Pfam; PF04644; Motilin_ghrelin; 1.

CC PRINTS; PR01624; GHRELIN.

CC DR PDom; PD332162; Preproghrelin; 1.

CC KW Hormone; Lipoprotein; Signal.

CC SIGNAL 1 23 By similarity.

CC PEPTIDE 24 50 Ghrelin (By similarity).

CC PROPEP 51 116 O-mannosyl in mature form (By similarity).

CC LIPID 26 26 O-octanoyl residue (By similarity).

CC CONFLICT 34 34 K -> E (in Ref. 2).

CC SEQUENCE 116 AA; 12793 MW; F5536DACSFA59B6 CRC64;

Query Match 70.0%; Score 101.5; DB 1; Length 116;

Best Local Similarity 71.4%; Pred. No. 9.4e-06;

	Matches	20;	Conservative	5;	Mismatches	2;	Indels	1;	Gaps	1;
Oy	1									
Db	24									
		GSSFLSPEDHOKL-QRKEAKKPSGRLKPR								

Search completed: December 3, 2005, 13:24:08
Job time : 234 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 3, 2005, 13:14:01, Search time 38 Seconds
(without alignments)
70.897 Million cell updates/sec

Title: US-10-622-124-31

Perfect score: 145

Sequence: 1 GSSFLSPERHQRVQQRKESKPPAKLQPR 28

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
1: p1r1:
2: p1r2:
3: p1r3:
4: p1r4:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	145	100.0	117	1 A59316	ghrelin precursor
2	138	95.2	117	1 B59316	ghrelin precursor
3	55	37.9	417	2 P90498	permease [imported
4	54	37.2	516	2 C72367	oligopeptide ABC t
5	53	36.6	1732	2 T14039	protein kinase (EC
6	52.5	36.2	1093	2 A47212	transcription fact
7	52	35.9	309	2 S08343	nodulin precursor
8	51	35.2	128	2 C42825	Kruppel-type zinc
9	51	35.2	304	1 M4W147	E4 protein - human
10	51	35.2	858	2 T00258	hypothetical prote
11	50	34.5	508	2 A33378	fasciclin III prec
12	50	34.5	716	2 G01627	androgen receptor
13	49.5	34.1	3938	2 T42761	Bassoon protein -
14	49.5	34.1	3942	2 T42730	Bassoon protein -
15	49	33.8	287	2 S45085	hypothetical prote
16	49	33.8	783	2 S51968	probable membrane
17	49	33.8	1702	2 T14050	protein kinase (EC
18	48.5	33.4	1234	2 T10160	hypothetical prote
19	48.5	33.4	2342	2 T13412	hypothetical prote
20	48	33.1	412	2 A55320	immunophilin FKBP4
21	48	33.1	805	2 T21957	hypothetical prote
22	48	33.1	1442	2 C82898	DNA polymerase III
23	47.5	32.8	766	2 G71160	probable histidine
24	47.5	32.8	962	2 C81060	translation initia
25	47.5	32.8	962	2 A81817	translation initia
26	47	32.4	379	2 S42529	Opaque-2-related p
27	47	32.4	408	2 S42529	opaque-2 protein -
28	47	32.4	419	2 S56073	opaque-2 protein -
29	47	32.4	437	2 A34800	Opaque-2 protein -

30	47	32.4	445	2 S23056	SLP2 protein - fru
31	47	32.4	460	2 S06022	regulatory protein
32	47	32.4	484	2 T18007	hypothetical prote
33	47	32.4	550	2 C86704	conserved hypothec
34	47	32.4	562	2 T34319	hypothetical prote
35	47	32.4	874	1 Q08B15	BSLF1 protein - hu
36	47	32.4	927	2 A48085	transcription fact
37	47	32.4	989	2 T48845	insulin II gene en
38	47	32.4	1225	2 T18954	hypothetical prote
39	47	32.4	1307	2 T25563	hypothetical prote
40	47	32.4	1400	2 T52359	hypothetical prote
41	46.5	32.1	239	2 D84004	hypothetical prote
42	46.5	32.1	981	1 F0MVGW	gag-ab1 polyprotei
43	46.5	32.1	1091	2 T34247	hypothetical prote
44	46.5	32.1	1107	2 T34246	hypothetical prote
45	46.5	32.1	1123	2 A39962	kinase-related tra

ALIGNMENTS

```

RESULT 1
A59316
ghrelin precursor - human
N:Alternate names: preproghrelin
C:Species: Homo sapiens (man)
C>Date: 16-Jun-2000 #sequence_revision 16-Jun-2000 #text_change 09-Jul-2004
C:Accession: A59316
R:Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K.
Nature 402, 656-660, 1999
A>Title: Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
A:Reference number: A59316; MUID:20067959; PMID:10604470
A:Accession: A59316
A>Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-117 <KOJ>
A:Cross-references: UNIPROT:Q9UNB3; UNIPARC:UPI00000362D3; GB:AB029434; NID:G6691571; PI
F:24-51/Product: ghrelin #status predicted <MKT>
F:52-117/Domain: carboxyl-terminal propeptide #status predicted <CTP>
F:26/Binding site: octanoate (Ser) (covalent) #status experimental

Query Match      100.0%  Score 145;  DB 1;  Length 117;
Best Local Similarity 100.0%;  Pred. No. 1.5e-12;
Matches 28;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

OY      1  GSSFLSPERHQRVQQRKESKPPAKLQPR 28
Db      24 GSSFLSPERHQRVQQRKESKPPAKLQPR 51

RESULT 2
B59316
ghrelin precursor - rat
N:Alternate names: preproghrelin
C:Species: Rattus norvegicus (Norway rat)
C>Date: 16-Jun-2000 #sequence_revision 16-Jun-2000 #text_change 09-Jul-2004
C:Accession: B59316
R:Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K.
Nature 402, 656-660, 1999
A>Title: Ghrelin is a growth-hormone-releasing acylated peptide from stomach.
A:Reference number: A59316; MUID:20067959; PMID:10604470
A:Accession: B59316
A>Status: not compared with conceptual translation
A:Molecule type: mRNA; protein
A:Residues: 1-117 <KOJ>
A:Cross-references: UNIPROT:Q9QYH7; UNIPARC:UPI000012B411; GB:AB029433; NID:G6691569; P
A:Experimental source: strain SD; tissue stomach endocrine cells

```

A:Note: submitted to GenBank, June 1999
 C:Comment: Ghrelin secreted by the stomach stimulates the release of somatotropin (growth hormone) from the pituitary gland.
 C:Superfamily: motilin
 C:Keywords: hormone, lipoprotein, stomach
 F:1-23/Domain: signal sequence #status predicted <SIG>
 F:24-51/Product: ghrelin #status predicted <MNT>
 F:52-117/Domain: carboxyl-terminal propeptide #status predicted <CTP>
 F:126/Binding site: octanoate (Ser) (covalent) #status experimental

Query Match 95.2% Score 138; DB 1; Length 117;
 Best Local Similarity 92.9% Pred. No. 1,3e-11;
 Matches 26; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Oy 1 GSSFLSPHQVQQRKESKKPPAKLQPR 28
 |||||
 Db 24 GSSFLSPHQVQQRKESKKPPAKLQPR 51

RESULT 3
 F90498
 permease [imported] - Sulfolobus solfataricus
 C:Species: Sulfolobus solfataricus
 C:Date: 24-May-2001 #sequence_revision 24-May-2001 #text_change 09-Jul-2004
 C:Accession: F90498
 R:She, Q.; Singh, R.K.; Confalonieri, F.; Zivanovic, Y.; Allard, G.; Anayez, M.J.; Chan-
 Jongs, I.; Jeffries, A.C.; Kozera, C.T.; Medina, N.; Peng, X.; Tnl-Ngoc, H.P.; Redder, F.
 arett, R.A.; Ragan, M.A.; Senses, C.W.; Van der Oost, J.
 submitted to GenBank, April 2001
 A:Description: Sulfolobus solfataricus complete genome.
 A:Reference number: A99139
 A:Accession: F90498
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-417 <KOR>
 A:Cross-references: UNIPROT:Q9JU76; UNIPARC:UPI0000064989; GB:AE006641; NID:g1316571; E
 C:Genetics:
 A:Gene: SS03147

Query Match 37.9% Score 55; DB 2; Length 417;
 Best Local Similarity 54.5% Pred. No. 7.8;
 Matches 12; Conservative 2; Mismatches 8; Indels 0; Gaps 0;

Oy 4 FLSPHQVQQRKESKKPPAKL 25
 |||||
 Db 198 FLMPESLRFRRKRRVKSPPAKL 219

RESULT 4
 C72367
 oligopeptide ABC transporter, permease protein - Thermotoga maritima (strain MSB8)
 C:Species: Thermotoga maritima
 C:Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 09-Jul-2004
 C:Accession: C72367
 R:Nelson, K.E.; Clayton, R.A.; Gill, S.R.; Gwim, M.L.; Dodson, R.J.; Haft, D.H.; Hickey,
 Garrett, M.M.; Stewart, A.M.; Cotton, M.D.; Pratt, M.S.; Phillips, C.A.; Richardson, D.
 C.M.
 Nature 399, 323-329, 1999
 A:Title: Evidence for lateral gene transfer between Archaea and Bacteria from genome seq
 A:Accession number: A72200; MUID:99287316; PMID:10360571
 A:Reference: C72367
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-516 <ARN>
 A:Cross-references: UNIPROT:Q9WZ03; UNIPARC:UPI00000D39E2; GB:AE001728; GB:AE000512; NID
 C:Genetics:
 A:Experimental source: strain MSB8
 A:Gene: TM0533

Query Match 37.2% Score 54; DB 2; Length 516;
 Best Local Similarity 45.8% Pred. No. 13;
 Matches 11; Conservative 2; Mismatches 11; Indels 0; Gaps 0;

Oy 2 SSFLSPHQVQQRKESKKPPAKL 25

```

Db      53 ADFLSPHMYEQSLKHSFAPPTKI 76
|||||
RESULT 5
T14039
protein kinase (EC 2.7.1.37), myotonic dystrophy-associated - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 20-Sep-1999 #sequence_rev1501 20-Sep-1999 #text_change 05-Oct-2004
C:Accession: T14039
R:Ljung, T.; Chen, X.Q.; Tan, I.; Manser, E.; Lim, L.
Mol. Cell. Biol. 18, 130-140, 1998
A:Title: Myotonic dystrophy kinase-related Cdc42-binding kinase acts as a Cdc42 effector
A:Reference number: Z17862; MID:198078670; PMID:9418861
A:Accession: T14039
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-1732 <LEU>
A:Cross-references: UNIPROT:O54874; UNIPARC:UPI000000E7B1A; EMBL:AF021935; NID:g2736150;
C:Genetics:
A:Gene: MRCK
A:Keywords: ATP, phosphotransferase
F:75-343/Domain: protein kinase homology <KIN>
F:1013-1062/Domain: protein kinase C zinc-binding repeat homology <KZN>

Query Match      36.6%; Score 53; DB 2; Length 1732;
Best Local Similarity 50.0%; Pred. No. 62;
Matches 10; Conservative 4; Mismatches 6; Indels 0; Gaps 0;

QY      3 SFLSPHQRVQQRKSKKPP 22
|||||
Db      1545 SFRVPEERHQRRRLRDP 1564
|||||

RESULT 6
A47212
transcription factor TMF, TATA element modulatory factor - human
C:Species: Homo sapiens (man)
C:Date: 22-Sep-1993 #sequence_rev1501 18-Nov-1994 #text_change 09-Jul-2004
C:Accession: A47212
R:Garcia, J.A.; Ou, S.H.; Wu, F.; Luis, A.J.; Sparkes, R.S.; Gaynor, R.B.
Proc. Natl. Acad. Sci. U.S.A. 89, 9372-9376, 1992
A:Title: Cloning and chromosomal mapping of a human immunodeficiency virus 1 "TATA" elem
A:Reference number: A47212; MID:93028466; PMID:1409643
A:Accession: A47212
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: nucleic acid
A:Residues: 1-1093 <GAR>
A:Cross-references: UNIPROT:P82094; UNIPARC:UPI0000137076; GB:L01042; NID:g184097; PIDN:
A:Experimental source: HeLa cells
A>Note: sequence extracted from NCBI backbone (NCBIP:115729)

Query Match      36.2%; Score 52.5; DB 2; Length 1093;
Best Local Similarity 50.0%; Pred. No. 45;
Matches 13; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

QY      2 SSFLSP-EHQVQQRKSKKPPAKLQ 26
|||||
Db      98 SFLSPDVQTIQKSPVSKPPAKSQ 123
|||||

RESULT 7
S08343
nodulin precursor - soybean
C:Species: Glycine max (soybean)
C:Date: 29-Jan-1993 #sequence_rev1501 29-Jan-1993 #text_change 09-Jul-2004
C:Accession: S08343; S08344; A27059
R:Franssen, H.J.; Thompson, D.V.; Idler, K.; Kormelink, R.; van Kammen, A.; Bleseling, T.
Plant Mol. Biol. 14, 103-106, 1990
A:Title: Nucleotide sequence of two soybean ENOD2 early nodulin genes encoding Ngm-75.
A:Reference number: S08343; MID:91322463; PMID:2101308
A:Accession: S08343
A:Molecule type: DNA

```

A:Residues: 1-309 <FRA>
A:Cross-references: UNIPROT:P08297; UNIPARC:UPI00001302AA; EMBL:X16875; NID:g18575; PIDN
A:Experimental source: errata Wayne
A:Genetics: CH1
A:Accession: S08344
A:Molecule type: DNA
A:Residues: 1-309 <FR2>
A:Cross-references: UNIPARC:UPI00001302AA; EMBL:X16876; NID:g18578; PIDN:CAA34759.1; PID
A:Experimental source: errata Wayne
A:Genetics: CH2
R:Franssen, H.J.; Nap, J.P.; Gloudemans, T.; Stiekema, W.; van Dam, H.; Govers, F.; Louw
Proc. Natl. Acad. Sci. U.S.A. 84, 4495-4499, 1987
A:Title: Characterization of cDNA for nodulin-75 of soybean: a gene product involved in
A:Reference number: A94164
A:Accession: A27059
A:Molecule type: mRNA
A:Residues: 69-309 <FRW>
A:Cross-references: UNIPARC:UPI0000177B5A
C:Genetics: <CH1>
A:Gene: ENOD2A
C:Genetics: <CH2>
A:Gene: ENOD2B
C:Superfamily: proline-rich protein 3
C:Keywords: nitrogen fixation; nodulation
F:1-25/Domain: signal sequence #status predicted <SIG>
F:26-309/Product: nodulin #status predicted <MAT>

Query Match 35.9%; Score 52; DB 2; Length 309;
Best Local Similarity 42.9%; Pred. No. 15;
Matches 9; Conservative 5; Mismatches 7; Indels 0; Gaps 0;

Qy 7 PEHQRVQQRKSKPPAKLP 27
Db 211 PEYQPPQKPPKPPKPPKPP 231

RESULT 8
C42825
Kruppel-type zinc finger protein ZNF69 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 04-Mar-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004
C:Accession: C42825
R:Aubry, M.; Marneau, C.; Zhang, F.R.; Zahed, L.; Figlewicz, D.; Delattre, O.; Thomas,
Genomics 13, 641-648, 1992
A:Title: Cloning of six new genes with zinc finger motifs mapping to short and long arms
A:Reference number: A42825; MUID:92347659; PMID:1639391
A:Accession: C42825
A:Status: preliminary; not compared with conceptual translation
A:Molecule type: nucleic acid
A:Residues: 1-128 <AUB>
A:Cross-references: UNIPROT:Q9UC07; UNIPARC:UPI000013C418
A:Note: sequence extracted from NCBI backbone (NCBIP:109772)

Query Match 35.2%; Score 51; DB 2; Length 128;
Best Local Similarity 36.4%; Pred. No. 8.2;
Matches 8; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GSSFLSPHQVQQRKSKPP 22
Db 65 GKAFPCPVYVRIHERHSRKP 86

RESULT 9
M4ML47
B4 protein - human papillomavirus type 47
C:Species: human papillomavirus type 47
A:Note: host Homo sapiens (man)
C:Date: 31-Mar-1991 #sequence_revision 31-Mar-1991 #text_change 09-Jul-2004
C:Accession: E35324
R:Kiyono, T.; Adachi, A.; Ishibashi, M.
Virology 177, 401-405, 1990
A:Title: Genome organization and taxonomic position of human papillomavirus type 47 infe
A:Reference number: A35324; MUID:90281611; PMID:2162112

A:Accession: E35324
A:Status: translation not shown
A:Molecule type: DNA
A:Residues: 1-304 <KIT>
A:Cross-references: UNIPROT:P22421; UNIPARC:UPI0000138386; GB:M32305; NID:g333062; PIDN:
C:Superfamily: papillomavirus type 5 B4 protein
C:Keywords: early protein

Query Match 35.2%; Score 51; DB 1; Length 304;
Best Local Similarity 39.1%; Pred. No. 20;
Matches 9; Conservative 6; Mismatches 8; Indels 0; Gaps 0;

Qy 5 LSPHQVQQRKSKPPAKLP 27
Db 79 LAPHHQGHQEDKQDTPPRP 101

RESULT 10
T00258
Hypothetical protein KIAA0606 - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 01-Feb-1999 #sequence_revision 01-Feb-1999 #text_change 09-Jul-2004
C:Accession: T00258
R:Nagase, T.; Ishikawa, K.; Miyajima, N.; Tanaka, A.; Kotani, H.; Nomura, N.; Ohara, O.
DNA Res. 5, 31-39, 1998
A:Title: Prediction of the coding sequences of unidentified human genes. IX. The complet
A:Reference number: Z14086; MUID:98290545; PMID:9628581
A:Accession: T00258
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-858 <NAG>
A:Cross-references: UNIPROT:O60346; UNIPARC:UPI000017C1BA; EMBL:AB011178; NID:g3043735;
A:Experimental source: brain
C:Genetics:
A:Note: KIAA0606

Query Match 35.2%; Score 51; DB 2; Length 858;
Best Local Similarity 38.1%; Pred. No. 56;
Matches 8; Conservative 7; Mismatches 6; Indels 0; Gaps 0;

Qy 8 BHQRVQQRKSKPPAKLP 28
Db 820 KHHQEQQQQQPPPPQLQ 840

RESULT 11
A33378
Fasciclin III precursor - fruit fly (Drosophila melanogaster)
C:Species: Drosophila melanogaster
C:Date: 21-Feb-1990 #sequence_revision 21-Feb-1990 #text_change 09-Jul-2004
C:Accession: A33378
R:Snow, P.M.; Bieber, A.J.; Goodman, C.S.
Cell 59, 313-323, 1989
A:Title: Fasciclin III: a novel homophilic adhesion molecule in Drosophila.
A:Reference number: A33378; MUID:90030406; PMID:2509076
A:Accession: A33378
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-508 <SNOW>
A:Cross-references: UNIPROT:P15278; UNIPARC:UPI0000074D4; GB:M27813; NID:g157423; PID:g
C:Genetics:
A:Gene: FlyBase:Fa3
A:Cross-references: FlyBase:FBgn0000636
C:Keywords: phosphoprotein; transmembrane protein

Query Match 34.5%; Score 50; DB 2; Length 508;
Best Local Similarity 50.0%; Pred. No. 45;
Matches 9; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

Qy 6 SPEHQVQQRKSKPPA 23
Db 428 SPEQQQQQQQKAKRLPA 445

Job time : 40 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: December 3, 2005, 13:04:06 ; Search time 185 Seconds
(without alignments)
66.501 Million cell updates/sec

Title: US-10-622-124-31

Perfect score: 145
Sequence: 1 GSSFLSPHQVQQRKESKPPAKIQPR 28

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

A_Geneseq_21:*
1: geneeqp19808:*
2: geneeqp19908:*
3: geneeqp20008:*
4: geneeqp20018:*
5: geneeqp20028:*
6: geneeqp20038:*
7: geneeqp20048:*
8: geneeqp20058:*
9: geneeqp20068:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	145	100.0	28	4 AAB60509	Aab60509 Human ghr
2	145	100.0	28	5 AAE19032	Aae19032 Human ghr
3	145	100.0	28	5 ABB09532	Abb09532 Human ghr
4	145	100.0	28	6 ABB80235	Abb80235 Human ghr
5	145	100.0	28	7 ADP17076	Adp17076 Human alb
6	145	100.0	28	8 ADE53681	Adf53681 Human ghr
7	145	100.0	28	8 ADU67173	Adj67173 Human ghr
8	145	100.0	28	8 ADL66822	Adl66822 Human ghr
9	145	100.0	28	8 ADN03336	Adn03336 Protein #
10	145	100.0	28	8 ADN03336	Adn03336 Exemplary
11	145	100.0	28	8 ADP42171	Adp42171 Ghrelin r
12	145	100.0	28	8 ADU61100	Adu61100 Human gro
13	145	100.0	28	9 ADV90277	Adv90277 Protease-
14	145	100.0	28	9 ADX83574	Adx83574 Human ghr
15	145	100.0	28	9 ADY80098	Ady80098 Amino aci
16	145	100.0	28	9 ADY72886	Ady72886 Human ghr
17	145	100.0	28	9 ADZ00357	Adz00357 Human ghr
18	145	100.0	28	9 ADZ20539	Adz20539 Ghrelin p
19	145	100.0	28	9 AEA00515	Aea00515 Human acy
20	145	100.0	28	9 AEA00516	Aea00516 Human ghr
21	145	100.0	28	9 AEA23453	Aea23453 Human ghr
22	145	100.0	28	9 AEC21037	Aec21037 Virus-11k
23	145	100.0	29	8 ADJ67207	Adj67207 Human ghr
24	145	100.0	29	8 ADJ67205	Adj67205 Human ghr

25	145	100.0	30	8 ADJ67261	Adj67261 Ghrelin m
26	145	100.0	60	8 ADK66754	Adk66754 Human ghr
27	145	100.0	91	6 AAE33410	Aae33410 Human exo
28	145	100.0	117	2 AAM87891	Aam87891 Protein d
29	145	100.0	117	3 AAY87236	Aay87236 Human sig
30	145	100.0	117	4 AAB20101	Aab20101 Zsig3 pr
31	145	100.0	117	4 AAB62649	Aab62649 Human zsl
32	145	100.0	117	4 AAM38890	Aam38890 Human pol
33	145	100.0	117	4 AAB60511	Aab60511 Human ghr
34	145	100.0	117	5 ABB78319	Abb78319 Amino aci
35	145	100.0	117	5 AAE23838	Aae23838 Human zsl
36	145	100.0	117	5 AAE15883	Aae15883 Human zsl
37	145	100.0	117	6 ABB58046	Abb58046 Human pro
38	145	100.0	117	6 ABB59124	Abb59124 Novel hum
39	145	100.0	117	6 ABB82636	Abb82636 Human sec
40	145	100.0	117	6 ABO17836	Abol7836 Novel hum
41	145	100.0	117	6 ABB60555	Abb60555 Human sec
42	145	100.0	117	6 ABB13937	Abb13937 Human pro
43	145	100.0	117	6 ABB81090	Abb81090 Human pro
44	145	100.0	117	6 ABB72522	Abb72522 Novel hum
45	145	100.0	117	6 ABB66790	Abb66790 Human pro

ALIGNMENTS

RESULT 1
AAB60509
ID AAB60509 standard; peptide; 28 AA.
XX
AC AAB60509;
XX
DT 24-APR-2001 (first entry)
XX
DE Human ghrelin, SEQ ID NO:3.
XX
KW Growth hormone secretagogue; GHS; ghrelin;
KW calcium concentration elevation; infant growth disorder;
KW growth hormone deficiency.
XX
XX Homo sapiens.
OS
XX
XX MO200107475-A1.
PN
XX
PD 01-FEB-2001.
XX
XX 24-JUL-2000; 2000WO-JP004907.
PF
XX
XX 23-JUL-1999; 99QP-00210002.
PR
XX 29-NOV-1999; 99YP-00338841.
PR 26-APR-2000; 2000JP-00126623.
XX
PA (KANG/) KANGAWA K.
XX
PI Kangawa K, Kojima M, Hosoda H, Matsuo H, Minamitake Y;
XX WPI; 2001-159704/16.
XX
XX New peptide compounds which induce growth hormone secretion and elevate
PT cell calcium concentrations, useful in treatment and diagnosis of infant
PT growth disorders.
XX
XX Claim 3; Page 181; 210pp; Japanese.
PS
XX
XX The invention relates to a novel peptide compound or its salt which
CC induces the secretion of growth hormone and/or elevates calcium ion
CC concentration in cells. The peptides are ghrelin homologues and are
CC characterised in that at least one amino acid has been substituted by a
CC modified amino acid and/or a non-amino acid compound. The invention also
CC encompasses the unmodified peptides; the DNA encoding the peptides;
CC vectors and host cells comprising such DNA; a method of producing the
CC peptides comprising recombinant production, optionally followed by
CC chemical modification; an antibody specific for a peptide of the

CC invention; and an assay and kit for detecting the peptides. The peptides
CC of the invention are useful for treating and/or diagnosing diseases
CC caused by a deficiency in growth hormone expression or activity. In
CC particular, they are useful for promoting infant growth due to growth
CC hormone deficiency. The compounds of the invention are safe with no
CC accompanying side effects. The present sequence represents a ghrelin-type
CC growth hormone secretagogue (GHS) of the invention

CC Sequence 28 AA;

Query Match 100.0%; Score 145; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 2,2e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28
Db 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28

RESULT 2
AAE19032

ID AAE19032 standard; peptide; 28 AA.

AC AAE19032;

DT 21-MAY-2002 (first entry)

DE Human ghrelin peptide analogue, compound 6.

XX Human; ghrelin analogue; growth-hormone secretagogue; GHS receptor; AIDS;
KM acquired immune deficiency syndrome; weight gain; chemotherapy; dialysis;
KM growth hormone; muscle mass; bone density; sexual dysfunction; anorexia;
KM wasting; radiation therapy; obesity; diabetes; retinopathy; hypertension;
KM cardiovascular disorder; gall stone; osteoarthritis; cancer; cyclostatic;
KM metabolic; immunomodulator; anti-HIV; anorectic; ophthalmological;
KM cardiac; litholytic; hepatocytic.

XX Homo sapiens.

OS WO200192292-A2.

PN 06-DEC-2001.

PD 25-MAY-2001; 2001WO-US017026.

PF 30-MAY-2000; 2000US-0207920P.

PR (MERI) MERCK & CO INC.

PA Bednarek M;

PI WPI; 2002-195531/25.

DR Truncated ghrelin analogs active at growth-hormone secretagogue receptor
PT useful for diagnosing or treating diseases such as anorexia, bulimia,
PT cancer, obesity, diabetes mellitus, hypertension, osteoarthritis.

PS Example 4; Page 34; 37pp; English.

XX The present invention relates to a truncated ghrelin analogue or their
CC salt, active at growth-hormone secretagogue (GHS) receptor. Ghrelin
CC analogue is useful for screening a compound capable of binding to GHS
CC receptor and for stimulating growth hormone secretion. Ghrelin agonist is
CC utilized for treating a growth hormone deficient state, increasing muscle
CC mass and bone density, treating sexual dysfunction in males or females,
CC facilitating a weight gain, maintenance of weight, maintenance of
CC physical functioning, recovery of physical function, and/or appetite
CC increase, or appetite increase is particularly useful for a patient
CC having a disease or disorder, or under going a treatment, accompanied by
CC weight loss such as anorexia, bulimia, cancer cachexia, acquired immune
CC deficiency syndrome (AIDS), wasting, cachexia and wasting in frail
CC elderly and examples of treatments accompanied by weight loss include
CC chemotherapy, radiation therapy, temporary or permanent immobilisation

CC and dialysis; and ghrelin antagonist is utilised to facilitate weight
CC loss, appetite decrease, weight maintenance, treat obesity, diabetes and
CC complications of diabetes including retinopathy, and/or cardiovascular
CC disorders, where excessive weight is a contributing factor to different
CC diseases including hypertension, diabetes, dyslipidemia, cardiovascular
CC diseases, gall stones, osteoarthritis and certain forms of cancers, and
CC bringing about a weight loss can be used for e.g. to reduce the
CC likelihood of such diseases and for treating such diseases. Ghrelin
CC analogue induces growth hormone release from primary-culture pituitary
CC cells in a dose-dependent manner without stimulating the release of other
CC pituitary hormones. Unlike longer length ghrelin, ghrelin analogue can be
CC synthesized easily and has increased solubility in physiological buffers.
CC The present sequence is human ghrelin peptide analogue

CC Sequence 28 AA;

Query Match 100.0%; Score 145; DB 5; Length 28;
Best Local Similarity 100.0%; Pred. No. 2,2e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28
Db 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28

RESULT 3
ABB09532

ID ABB09532 standard; peptide; 28 AA.

AC ABB09532;

DT 22-OCT-2002 (first entry)

DE Human ghrelin.

XX Human; ghrelin; appetite; food intake; agonist; analogue; undernutrition;
KM anorexia; cachexia; malignant disease; infection; inflammatory disease;
KM weight loss; antagonist; obesity; anorectic; anabolic.

XX Homo sapiens.

OS Key Location/Qualifiers

FT Modified-site 3 /note="n-octanoyl-Ser"

PN WO200260472-A1.

PD 08-AUG-2002.

PF 31-JAN-2002; 2002WO-JP000765.

PR 31-JAN-2001; 2001JP-00024423.

PA (CHUS) CHUGAI SEIYAKU KK.

PI Inui A, Asakawa A, Kaga T;

PI WPI; 2002-619206/66.

DR Remedies for diseases with hypo-nutrition status e.g. inappetence and
PT cachexia, containing ghrelin or its analogs including agonists and
PT antagonists.

PS Disclosure; Fig 1A; 50pp; Japanese.

XX The invention relates to the use of ghrelin or its analogues for the
CC treatment of diseases associated with undernutrition such as anorexia,
CC and also relates to the use of ghrelin antagonists for the prevention or
CC treatment of obesity. The invention additionally discloses a method for
CC screening ghrelin agonists or antagonists by measuring the amount of food
CC intake, neuropeptide Y (NPY) expression, binding of NPY to NPY receptor
CC Y1, oxygen consumption, gastric emptying, or activity of the vagus nerve.
CC Intracerebroventricular (ICV) administration of ghrelin in animals was

CC which was fused with human albumin to create a novel albumin fusion
CC protein of the invention. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at http://wipo.int/pub/publishedpat_sequences
XX
SQ Sequence 28 AA;

Query Match 100.0%; Score 145; DB 7; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.2e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GSSFLSPHQRVQQRKSKKPPAKLQPR 28
|||
Db 1 GSSFLSPHQRVQQRKSKKPPAKLQPR 28

RESULT 6

ADF53681
ID ADF53681 standard; peptide; 28 AA.

AC ADF53681;

DT 12-FEB-2004 (first entry)

DE Human ghrelin-related peptide - SEQ ID 1.

XX ghrelin; growth hormone secretion promoter receptor; GHS; GHS-R;
XX anorectic; vulnery; immunostimulant; muscular; dermatological;
XX anabolic; dwarfism; myoblast; bone regeneration; burn; gonadotrophin;
XX ovulation; prednisone treatment; immune deficiency; weight reduction;
XX fatty tissue; skin atrophy; human.

OS Homo sapiens.

PN WO2003097083-A1.

PD 27-NOV-2003.

PF 21-MAY-2003; 2003WO-JP006349.

PR 21-MAY-2002; 2002JP-00146155.

PA (SUNR) DAIICHI SUNTORY PHARMA CO LTD.

PA (KANG)/KANGAWA K.

PI Minamitake Y, Matsumoto M;

DR WPI; 2004-012483/01.

PT Aqueous composition of ghrelin at neutral to acid pH for improved
PT stability, for treating growth hormone deficiency and related conditions.

XX Example 1; SEQ ID NO 1; 58pp; Japanese.

CC The invention relates to a novel aqueous pharmaceutical composition
CC comprising a ghrelin which is an endogenous growth hormone secretion
CC promoter (GHS) to a growth hormone secretion promoter receptor (GHS-R),
CC in a solution of pH 2-7. The composition of the invention demonstrates
CC endocrine, vulnery, immunostimulant, muscular, dermatological and
CC anabolic activities and may be useful for treating dwarfism, increasing
CC muscle amount and strength in growth hormone deficiency, activating
CC myoblasts and bone regeneration in normal individuals, treating serious
CC burns in children and accompanying gonadotrophin in induction of
CC ovulation. Furthermore, the composition may be used to prevent protein
CC metabolic anomaly during prednisone treatment, to enhance T cells in
CC immune deficiency and to suppress weight reduction, fatty tissue spread
CC and skin atrophy in old age. The current sequence is that of the ghrelin-
CC related peptide of the invention.

XX Sequence 28 AA;

Query Match 100.0%; Score 145; DB 8; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.2e-12;

Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GSSFLSPHQRVQQRKSKKPPAKLQPR 28
|||
Db 1 GSSFLSPHQRVQQRKSKKPPAKLQPR 28

RESULT 7
AD67173
ID AD67173 standard; peptide; 28 AA.

AC AD67173;

DT 06-MAY-2004 (first entry)

DE Human ghrelin peptide antigen #1.

XX anorectic; core particle; antigenic determinant; ghrelin; P-pilin;
XX antigenic array.

OS Homo sapiens.

PN WO2004009124-A2.

PD 29-JAN-2004.

PF 18-JUL-2003; 2003WO-EP007849.

PR 19-JUL-2002; 2002US-0396638P.

PA (CYTO-) CYTOS BIOTECHNOLOGY AG.

PI Bachmann MF, Fulurija A;

DR WPI; 2004-132866/13.

PT New composition comprising a core particle having a first attachment site
PT and an antigen or antigenic determinant which is a ghrelin or ghrelin
PT peptide having a second attachment site, useful for treating obesity.

XX Claim 25; SEQ ID NO 31; 175pp; English.

CC The invention relates to a new composition comprising: (i) a core
CC particle with at least one first attachment site; and (ii) at least one
CC antigen or antigenic determinant with at least one second attachment
CC site, where the antigen or antigenic determinant is ghrelin or a ghrelin
CC peptide, and where the second attachment site being consisting of an
CC attachment site not naturally occurring with the antigen or antigenic
CC determinant and an attachment site naturally occurring with the antigen
CC or antigenic determinant, where the second attachment site is capable of
CC association to the first attachment site, and where the ghrelin or a
CC ghrelin peptide and the core particle interact through the association to
CC form an ordered and repetitive antigen array. The composition is useful
CC for treating obesity. The repetitive array may form part of a phase or
CC bacterial display array. This peptide corresponds to a ghrelin peptide of
CC the invention.

XX Sequence 28 AA;

Query Match 100.0%; Score 145; DB 8; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.2e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GSSFLSPHQRVQQRKSKKPPAKLQPR 28
|||
Db 1 GSSFLSPHQRVQQRKSKKPPAKLQPR 28

RESULT 8

ADL66822
ID ADL66822 standard; peptide; 28 AA.

AC ADL66822;

```

XX 20-MAY-2004 (first entry)
DT
XX Human Ghrelin-related growth hormone secretagogue peptide 1.
DE
XX drug; Ghrelin; growth hormone secretagogue; human.
XX
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FH Modified-site 3 /label= OTHER
FT /note= "OTHER = n-octanoyl residue"
FT
XX
XX WO2003084983-A1.
XX
XX 16-OCT-2003.
XX
XX 10-APR-2003; 2003WO-JP004590.
XX
XX 11-APR-2002; 2002JP-00109761.
XX
XX (DAI-I) DAICHI SUNTORY PHARMA CO LTD.
XX (KANG/) KANGAWA K.
XX
XX Minamitake Y, Matsumoto M, Makino T;
PI
XX WPI; 2004-098839/10.
XX
XX Producing modified peptides or proteins with physiological activity
PT comprises fusing side chain-modified peptide fragments obtained by solid-
PT phase synthesis and non-modified peptides by genetic modification.
XX
XX Disclosure; SEQ ID NO 1; 120pp; Japanese.
XX
XX The invention relates to a novel method for producing protected or
CC modified peptide fragments containing desired sequences of amino acids
CC and/or non-amino acids, at least one of which is suitably protected for
CC preparing the peptide fragment with use of a weakly acidic-eliminating
CC resin to enable cleavage from the resin under weakly acidic conditions.
CC The method of the invention may be used for producing modified peptide
CC fragments or proteins and producing protected peptide fragments that do
CC not contain any modified (non-)amino acids for application as drugs. The
CC current sequence is that of a Ghrelin-related growth hormone secretagogue
CC peptide of the invention.
XX
XX Sequence 28 AA;
SQ
XX
XX Query Match 100.0%; Score 145; DB 8; Length 28;
XX Best Local Similarity 100.0%; Pred. No. 2.2e-12;
XX Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28
QY |||||
XX 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28
DB |||||
XX
XX RESULT 9
XX ADN12076
XX ID ADN12076 standard; protein; 28 AA.
XX
XX ADN12076;
XX
XX 17-JUN-2004 (first entry)
XX
XX Protein #1 associated with growth hormone secretagogue receptor.
DE
XX diabetes; growth hormone secretagogue receptor; GHS-R; Antidiabetic;
XX Anorectic; obesity; blood sugar level; appetite.
XX
XX Homo sapiens.
XX
XX WO2004004772-A1.
XX
XX

```

```

XX 15-JAN-2004.
XX
XX 03-JUL-2003; 2003WO-JP008482.
XX
XX 05-JUL-2002; 2002JP-00197582.
XX
XX (CHUS ) CHUGAI SEIYAKU KK.
XX
XX Inui A, Asakawa A;
XX
XX WPI; 2004-099347/10.
XX
XX Growth hormone secretagogue receptor antagonist for treatment of
PT diabetes, obesity and appetite control.
PT
XX
XX Disclosure; SEQ ID NO 1; 44pp; Japanese.
XX
XX The present invention relates to a treatment and preventative agent for
CC diabetes comprises growth hormone secretagogue receptor (GHS-R)
CC antagonist, for treatment and prevention of diabetes, obesity, for
CC lowering blood sugar levels and for use in controlling appetite. The
CC present sequence represents a protein associated with growth hormone
CC secretagogue receptor.
XX
XX Sequence 28 AA;
SQ
XX
XX Query Match 100.0%; Score 145; DB 8; Length 28;
XX Best Local Similarity 100.0%; Pred. No. 2.2e-12;
XX Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28
QY |||||
XX 1 GSSFLSPFHQRVQQRKSKKPPAKLQPR 28
DB |||||
XX
XX RESULT 10
XX ADN03336
XX ID ADN03336 standard; peptide; 28 AA.
XX
XX ADN03336;
XX
XX 17-JUN-2004 (first entry)
XX
XX Exemplary peptide ligand for proteome analysis #62.
XX
XX Peptide ligand; proteome; capture compound; mass spectrometry;
XX protein separation;
XX matrix assisted laser desorption ionisation-time of flight; MALDI-TOF.
XX
XX Unidentified.
XX
XX US2003119021-A1.
XX
XX 26-JUN-2003.
XX
XX 16-JUL-2002; 2002US-00197954.
XX
XX 16-JUL-2001; 2001US-0306019P.
XX
XX 21-AUG-2001; 2001US-0314123P.
XX
XX 11-MAR-2002; 2002US-0363433P.
XX
XX (KOST/) KOSTER H.
XX (SIDD/) SIDDIOI S.
XX (LITV/) LITTLE D P.
XX
XX Koster H, Siddiqui S, Little DP;
PI
XX
XX WPI; 2004-059185/06.
XX
XX Collection of capture compounds capable of binding to biomolecules to
PT form complexes that are stable under mass spectrometry conditions, useful
PT for analysis of biomolecules, especially proteins.
XX
XX

```

XX Disclosure; SEQ ID NO 62; 165bp; English.
PS
XX The invention relates to a collection of capture compounds capable of
CC binding to biomolecules to form complexes that are stable under mass
CC spectrometry conditions. The formulae for the capture compounds comprises
CC sets of compounds of formula (I)-(III) given in the specification. Also
CC included are analysis of biomolecules (by contacting a composition
CC comprising a biomolecule with the above collection and identifying or
CC detecting bound biomolecules), separating protein conformers (by
CC contacting a composition comprising a biomolecule with the above
CC collection, separating the members of the collection and identifying
CC bound proteins), reducing diversity of a complex mixture of biomolecules
CC (by contacting the mixture with the above collection and separating each
CC set of complexes of capture compounds with biomolecules from the other
CC sets) and identifying phenotype-specific biomolecules (by sorting cells
CC from a single subject into sets according to a phenotype, contacting
CC mixtures of biomolecules from each set with the above collection and
CC comparing the patterns of biomolecule binding from each set). The
CC collection of capture compounds is useful for the analysis of
CC biomolecules, especially proteins (e.g. analysis of a proteome), using
CC mass spectrometry, especially matrix assisted laser desorption/ionisation
CC -time of flight (MALDI-TOF) mass spectrometry. The present sequence is an
CC exemplary peptide ligand which may be incorporated into a capture
CC compound of the invention.
XX
SQ Sequence 28 AA;
Query Match 100.0%; Score 145; DB 8; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.2e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
Db 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
RESULT 11
ADU61100
ID ADU61100 standard; peptide; 28 AA.
XX
AC ADU61100;
XX
DT 21-OCT-2004 (first entry)
XX
DE Ghrelin related peptide ligand, SEQ ID 62.
XX
KW Human; ligand; Ghrelin.
XX
OS Homo sapiens.
XX
PN WO2004064972-A2.
XX
PD 05-AUG-2004.
XX
PF 16-JAN-2004; 2004WO-US001037.
XX
PR 16-JAN-2003; 2003US-0441398P.
XX
PA (HKPH-) HK PHARM INC.
XX
PA (KOE/) KOESTER H.
XX
PI Koester H, Little DP, Siddiqi SM, Grealish MP, Marappan S;
PI Haseman CF, Yip P;
XX
DR WPI; 2004-642213/62.
XX
PT Identifying drug non-target biomolecules in mixture of biomolecules
PT involves interacting mixture of biomolecules with capture compounds
PT having high binding affinity and analyzing captured biomolecules to
PT identify drug non-targets.
XX
PS Disclosure; SEQ ID NO 62; 368bp; English.

XX The present invention relates to a method for identifying drug non-target
CC biomolecules in a mixture of biomolecules. The method comprises
CC interacting mixture with capture compounds having moiety X which
CC covalently binds to biomolecules with high affinity, moiety Y that
CC increases selectivity of binding so that the capture compound binds to
CC fewer biomolecules, and moiety Z for preventing X and Y, and analysing
CC captured biomolecules to identify drug non-targets. The capture compound
CC also optionally comprises a sorting function moiety Q and or a solubility
CC function moiety W. The selectivity function moiety Y serves to modulate
CC the reactivity function by reducing the number of groups to which the
CC reactivity function moiety X bind, such as by steric hindrance and other
CC interactions. Y is optionally a peptide ligand (ADU6112-ADU62256).
XX
SQ Sequence 28 AA;
Query Match 100.0%; Score 145; DB 8; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.2e-12;
Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
Db 1 GSSFLSPHQHVQQRKSKKPPAKLQPR 28
RESULT 12
ADU61100
ID ADU61100 standard; peptide; 28 AA.
XX
AC ADU61100;
XX
DT 27-JAN-2005 (first entry)
XX
DE Human growth hormone secretagogue #1.
XX
KW growth hormone; secretagogue; hepatopathy; intracellular;
KW calcium ion; concentration; growth hormone;
KW secretion inducer receptor; GHS-R; hepatitis; liver cirrhosis;
KW liver failure; viral hepatitis; alcoholic hepatitis;
KW drug induced hepatitis; autoimmune hepatitis; recover; liver function;
KW liver transplantation.
XX
OS Homo sapiens.
XX
PN WO2004096260-A1.
XX
PD 11-NOV-2004.
XX
PF 30-APR-2004; 2004WO-JP006365.
XX
PR 30-APR-2003; 2003JP-00126088.
XX
PA (KANG/) KANGAWA K.
XX
PI Kangawa K, Hosoda H;
XX
DR WPI; 2004-813823/80.
XX
PT Preventive or therapeutic agent of hepatopathy such as hepatitis or liver
PT cirrhosis, comprises polypeptide having activity that raises
PT intracellular calcium ion concentration by binding with growth hormone
PT secretion inducer receptor.
XX
PS Claim 1; SEQ ID NO 1; 107bp; Japanese.
XX
XX This sequence represents a growth hormone secretagogue which was used in
CC the preventive or therapeutic agent of hepatopathy of the invention. The
CC therapeutic agent has activity which raises intracellular calcium ion
CC concentration by binding with growth hormone secretion inducer receptor
CC (GHS-R) and comprises a polypeptide which raises the intracellular
CC calcium ion concentration by binding with GHS-R or its salt as an active
CC ingredient. The therapeutic agent of the invention is useful for
CC preventing or treating hepatopathy such as hepatitis, liver cirrhosis,

CC and liver failure, hepatitis such as viral hepatitis, alcoholic
 CC hepatitis, drug induced hepatitis and autoimmune hepatitis, and for
 CC recovering the liver function after liver transplantation, in a mammal
 CC such as human. The method of treatment involves administering the agent
 CC to the mammal.

XX Sequence 28 AA;

Query Match 100.0%; Score 145; DB 8; Length 28;
 Best Local Similarity 100.0%; Pred. No. 2.2e-12;
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GSSFSPSHORVQQRKSKKPPAKLQPR 28
 Db 1 GSSFSPSHORVQQRKSKKPPAKLQPR 28

RESULT 13

ID ADV90277 standard; peptide; 28 AA.

XX ADV90277;

DT 10-MAR-2005 (first entry)

XX Protease-hydrolysed polypeptide #54.

XX Protease; immune disorder; inflammation; musculoskeletal disease;
 KW dermatological disease; gastrointestinal disease; endocrine disease;
 KW metabolic disorder; cancer; hematological disease;
 KW cardiovascular disease; neurological disease; neurodegenerative disease;
 KW growth disorder; respiratory disease; genitourinary disease;
 KW gynecological disorder; nutritional disorder; infection; cytostatic;
 KW gastrointestinal-gen.; antiinflammatory; antiasthmatic; analgesic;
 KW antiarthritic; osteopathic; antidiabetic; nephrotoxic;
 KW cardiovascular-gen.; immunosuppressive; respiratory-gen.; antipeptidic;
 KW antiallergic; dermatological; enzyme; hydrolysis.

XX Homo sapiens.

XX WO2004113522-A1.

XX 29-DEC-2004.

PF 18-JUN-2004; 2004WO-EP051173.

XX PR 18-JUN-2003; 2003EP-00013819.

XX PR 10-NOV-2003; 2003EP-00025851.

XX PR 11-NOV-2003; 2003EP-00025871.

XX PR 11-FEB-2004; 2004EP-00003058.

XX PA (DIRE-) DIREVO BIOTECH AG.

XX PI Hauptz U, Koltermann A, Scheidig A, Voetemeier C, Ketting U;

XX WPI; 2005-057985/06.

PT Processes with defined specificity for a target substrate useful for
 PT treating a specific disease related to the target substrate, such as
 PT cancer, asthma, diabetes, inflammatory disorders and psoriasis.

XX Claim 34; SEQ ID NO 107; 250pp; English.

XX The invention relates to the use of a protease with defined specificity
 CC for a target substrate for preparing a medicament for the treatment of a
 CC specific disease related to the target substrate. The invention also
 CC relates to a pharmaceutical or diagnostic composition comprising one or
 CC more enzymes in the use cited, optionally comprising pharmaceutically or
 CC diagnostically acceptable carriers, excipients and/or auxiliary agents, a
 CC method for cleaving a target substrate in vivo or in vitro comprising
 CC contacting the target substrate with a protease as cited in the use
 CC mentioned, and a method for treatment of a disease in a patient connected
 CC with a specific target substrate comprising administering to the patient

CC a protease with defined specificity for the specific target substrate.
 CC The protease hydrolyzes the target substrate and eliminates or reduces
 CC one or more biological activities, physico-chemical properties or
 CC pharmacological properties of the target protein and/or activates or
 CC increases one or more biological activities, physico-chemical properties
 CC or pharmacological properties of the target protein, and/or adds one or
 CC more biological activities, physico-chemical properties or
 CC pharmacological properties to the target protein. The protease may be
 CC administered to treat immune disorders, inflammatory disorders,
 CC musculoskeletal diseases, dermatological diseases, gastrointestinal
 CC diseases, endocrine diseases, metabolic disorder, cancer, hematological
 CC diseases, cardiovascular diseases, neurological diseases,
 CC neurodegenerative diseases, growth disorders, respiratory diseases,
 CC genitourinary diseases, gynecological disorders, nutritional disorders
 CC and infections. This sequence represents a polypeptide hydrolysed by a
 CC protease used in the scope of the invention.

XX Sequence 28 AA;

Query Match 100.0%; Score 145; DB 9; Length 28;
 Best Local Similarity 100.0%; Pred. No. 2.2e-12;
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GSSFSPSHORVQQRKSKKPPAKLQPR 28
 Db 1 GSSFSPSHORVQQRKSKKPPAKLQPR 28

RESULT 14

ID ADX83574 standard; peptide; 28 AA.

XX ADX83574;

DT 05-MAY-2005 (first entry)

XX Human ghrelin-like compound SEQ ID NO 1.

XX anabolic; cytostatic; appetite stimulant; pharmaceutical; secretagogue;
 KW anabolic; nutritional disorder; cachexia; cancer; cytostatic; neoplasm;
 KW respiratory disease; gastrointestinal disease; lung tumor;
 KW pancreas tumor; liver tumor; gastrointestinal tumor;
 KW ghrelin-like compound.

XX Homo sapiens.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 3 //label= OTHER
 FT /note= "OTHER= Fatty acid C7H15"

XX WO2005014032-A2.

XX PD 17-FEB-2005.

PF 06-AUG-2004; 2004WO-DK000529.

XX PR 06-AUG-2003; 2003DK-00001139.

XX PR 14-AUG-2003; 2003DK-00001140.

XX PR 14-AUG-2003; 2003US-0494815P.

XX PR 14-AUG-2003; 2003US-0494816P.

XX PR 05-SEP-2003; 2003DK-00001283.

XX PR 24-OCT-2003; 2003DK-00001569.

XX PR 24-OCT-2003; 2003DK-00001570.

XX PR 07-APR-2004; 2004DK-00000570.

XX PA (GAST-) GASTROTECH PHARMA AS.

XX PI Lange BH, Hansen C, Nilsson H;

XX WPI; 2005-202317/21.

PT Use of secretagogue compound for preparation of medicament for
 PT prophylaxis or treatment of cancer cachexia in individual in need of such
 PT treatment.

PS Example 2; SEQ ID NO 1; 148bp; English.

CC The invention describes the use of a secretagogue compound (C1) for the
 CC preparation of a medicament for the prophylaxis or treatment of cancer
 CC cachexia in an individual in need of such treatment. Also described are:
 CC a ghrelin-like compound of formula (I) as mentioned above; a
 CC pharmaceutical composition (PC) comprising the ghrelin-like compound as
 CC described above, or its salt, and carriers, vehicles and/or excipients; a
 CC medical packaging (MP) comprising one or more dosage units of PC;
 CC monitoring the blood level of a treatment of an individual with C1, involving
 CC measuring the effect of a treatment of an individual of IGF-1 (insulin like growth
 CC factor 1), IGFBP-3 (insulin-like growth factor binding protein 3) and/or
 CC ALS (Acetolactate synthase); and preventing or treating cachexia,
 CC involves administering to an individual, C1 and an effective amount of a
 CC NSAID medicament. C1 is useful in the preparation of a medicament for
 CC prophylaxis or treatment of cancer cachexia in an individual in need of
 CC treatment. The cancer cachexia is caused by a catabolic disorder or
 CC anorectic disorder. The individual is suffering from a cancer chosen from
 CC lung cancer, pancreatic cancer, liver cancer and gastrointestinal tract
 CC cancers. C1 is useful in treating or preventing cancer cachexia that
 CC leads to stimulation of appetite, stimulation of food intake, stimulation
 CC of weight gain or weight maintenance, and/or increased body fat mass. C1
 CC is useful in preventing or treating cancer cachexia, which involves
 CC administering C1 to an individual. C1 is useful for preventing or
 CC treating cancer, which involves administering C1 to an individual, in
 CC combination with an anti-neoplastic treatment. The anti-neoplastic
 CC treatment is radiotherapy or chemotherapy. This is the amino acid
 CC sequence of a human ghrelin-like compound.

XX Sequence 28 AA;

Query Match 100.0%; Score 145; DB 9; Length 28;
 Best Local Similarity 100.0%; Pred. No. 2,2e-12;
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GSSFLSPBHQVQQRKSKKPPAKLQPR 28
 Db 1 GSSFLSPBHQVQQRKSKKPPAKLQPR 28

RESULT 15

ID ADY80098 standard; peptide; 28 AA.

XX ADY80098;

DT 02-JUN-2005 (first entry)

XX Amino acid sequence of human ghrelin.

XX ghrelin; eating-disorders-gen.; psychiatric disorder; antidiabetic;
 KW anorectic; genetic disorder; nutritional disorder;
 KW gastrointestinal disease; cardiovascular-gen.; anxiety disorder; obesity;
 KW non-insulin dependent diabetes mellitus; Prader-Willi syndrome;
 KW eating disorder; hyperphagia; gastric motility disorder; cancer;
 KW neoplasm; cytostatic; cardiovascular disease; nootropic;
 KW antibody therapy.

XX Homo sapiens.

OS Key Location/Qualifiers

FT Misc-difference 28 /note="optionally absent"

XX MO2005026211-A2.

XX 24-MAR-2005.

XX 02-SEP-2004; 2004WO-US025604.

XX 05-SEP-2003; 2003US-0500496P.
 PR 18-MAY-2004; 2004US-0572249P.
 PR 23-JUN-2004; 2004US-0582111P.
 XX (ELIL) LILLY & CO ELI.

XX Helman ML, Kikly KK, Manetta JV, Witcher DR;

PI WPI; 2005-233485/24.

XX New anti-human ghrelin (hghrelin) monoclonal antibody, useful for

PT treating or preventing obesity or a related disorder e.g., non-insulin

PT dependent diabetes mellitus, Prader-Willi syndrome, eating disorders, and

PT anxiety.

XX Disclosure; SEQ ID NO 19; 88bp; English.

PS The specification describes a monoclonal antibody that specifically binds
 CC human ghrelin at an epitope localized to amino acids 4-20. The
 CC complementarily determining regions (CDRs) of such antibodies are used to
 CC construct chimeric or humanized antibodies. Pharmaceutical compositions
 CC comprising the antibody of the invention are useful for treating or
 CC preventing obesity, or a related disorder such as non-insulin dependent
 CC diabetes mellitus, Prader-Willi syndrome, eating disorders, hyperphagia,
 CC impaired satiety, anxiety, gastric motility disorders, cancer and
 CC cardiovascular disorders. The present sequence represents human ghrelin.

XX Sequence 28 AA;

Query Match 100.0%; Score 145; DB 9; Length 28;
 Best Local Similarity 100.0%; Pred. No. 2,2e-12;
 Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GSSFLSPBHQVQQRKSKKPPAKLQPR 28
 Db 1 GSSFLSPBHQVQQRKSKKPPAKLQPR 28

Search completed: December 3, 2005, 13:20:10
 Job time : 188 secs